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ABSTRACT 
 
 
 425 million people have diabetes worldwide, and by 2045 this number is 
estimated to increase to 629 million. The risk for cardiovascular diseases such as 
cardiomyopathy, hypertension, and atherosclerosis increase 5 and 2-fold for diabetic 
women and men respectively. Diabetic cardiomyopathy (DCMP) is a ventricular 
dysfunction that occurs in patients with diabetes independent of coronary artery disease, 
hypertension or valvular abnormalities. Hyperglycemia and dyslipidemia cause metabolic 
disturbances that adversely affect myocardial cells and extracellular matrix. These 
modifications alter overall myocardial structure and cardiac function, which can lead to 
heart failure.  
 As of now there is no specific marker for this disease and diagnosis is the same as 
other cardiomyopathies. Elucidating early stages of this disease is vital for early 
diagnosis, treatment, and possible therapy targets. Currently, rodent models and 2D cell 
cultures have been employed to analyze DCMP, however there are notable differences 
between rodents and humans that provide challenges when studying DCMP and cell 
cultures lack an extracellular matrix and dynamic environment crucial to the progression 
of this disease. 
Our overall goal was to use tissue engineering to bridge this gap by developing 
platforms to study pathological mechanisms at the cellular and extracellular level. We 
examined cardiac tissue engineered constructs in: (1) a perfusion 3D Kube 
minibioreactor and (2) an electromechanical bioreactor customized in our lab. Each 
platform contained decellularized myocardium seeded with human cardiomyocytes for 
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two weeks; “diabetic” conditions were simulated by increased glucose concentration. We 
were able to better mimic physiological conditions with our electromechanical 
bioreactor, compared to static and non-diabetic conditions, as well as to 2D cell culture. 
Methods for detecting cellular and matrix changes associated with DCMP were validated 
in a type 1 diabetic rodent model. Our tissue engineering platform shows promise for 
unveiling early cellular and matrix modifications in DCMP. This system could also be 
useful for studying human cells in other cardiac diseases, test treatments, and 
precondition myocardial-like tissue prior to implantation. 
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CHAPTER 1: REVIEW OF LITERATURE 
1.1 Introduction  
 The total global economic burden of diabetes mellitus in 2017 was estimated at 
$850 billion.1 425 million people have diabetes worldwide, and by 2045 this number is 
estimated to increase to 629 million.1 The risk for cardiovascular disease increases 5 and 
2 fold for diabetic women and men respectively.2 Diabetics have higher instances of 
cardiovascular disease such as diabetic cardiomyopathy, hypertension, and 
atherosclerosis, with elevated occurrences of myocardial infarctions and strokes within 
these patients due to atherosclerotic plaque ruptures.3 Diabetic cardiomyopathy (DCMP) 
can manifest in diabetic patients and it is estimated 19-26% of diabetic patients 
experience heart failure.4 DCMP is a ventricular dysfunction that occurs in patients with 
diabetes independent of coronary artery disease, hypertension or valvular abnormalities. 
Excessive utilization of circulating free fatty acids (FFA) creates a highly oxidative 
environment that supersedes the endogenous antioxidant defense mechanism of cells, 
leading to oxidative stress, lipotoxicity, autophagy, and apoptosis of cardiomyocytes. The 
hyperglycemic environment causes the formation and accumulation of advanced 
glycation endproducts (AGEs) in the extracellular matrix, fibrosis, and, lastly, heart 
failure.5 As of now, mainly rodent models and two dimensional (2D) cell cultures have 
been employed to analyze DCMP. However, there are notable differences between 
rodents and humans that provide challenges when studying DCMP and 2D cultures lack a 
dynamic, three dimensional (3D) environment crucial to the progression of this disease.6 
There is a need for a more accurate model to investigate DCMP for early diagnosis and 
 2 
test potential therapies. This gap can be bridged with the development of a reproducible, 
native-like tissue engineered model of the myocardium utilizing the tissue engineering 
paradigm of combining a scaffold, cells, and biochemical and physical stimuli.  
1.2 The Heart and Myocardium 
The heart is responsible for pumping blood throughout the body to supply 
oxygen, nutrient, and waste exchange. It is a highly stressed organ as it beats between 60 
and 100 beats per minute. It is comprised of four chambers, four heart valves, and utilizes 
a network of blood vessels in the circulatory system for transportation.7 Within the body, 
the heart is located left to the midline posterior to the sternum and rotated slightly so that 
its right border is located more anteriorly, and the left border is located more posteriorly. 
A fibrous sac and serous lining called the pericardium, surrounds the heart to provide an 
almost frictionless environment for the continuous movement of this organ. The normal 
adult human heart is typically 12cm in length, 8cm wide, 6cm thick, and weighs between 
250 and 350 grams.8 
 
Figure 1.1: The layers of the heart wall.7 
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The heart wall consists of three layers; the epicardium, myocardium, and 
endocardium with blood vessels and capillaries incorporated (Figure 1.1). The outer 
epicardium is comprised of epithelium and connective tissue and fat; the middle 
myocardium is made of mainly cardiomyocytes (CMs) and fibroblasts (FBs); and the 
inner endocardium contains endothelium and areolar connective tissue.7 
1.2.1 The Extracellular Matrix of the Myocardium 
The extracellular matrix (ECM) of healthy myocardium is a dynamic 
environment, undergoing constant, balanced turnover in its normal state. It is made of 
collagens (type I, III, IV, V, and VI), elastin, glycoproteins (laminins, fibronectin, 
periostin, fibromodulin, and vitronecin), proteoglycans (versican, lumican, and biglycan), 
glycosaminoglycans (hyaluronic acid and dermatan sulfate), and matricellular proteins.9  
 
Figure 1.2: Scanning electron microscopy (SEM) image of acellular myocardium, illustrating the 
collagenous network of the ECM that supports native cells.10 Arrows=cell voids. 
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These extracellular molecules are secreted by cells in the heart, mainly the FBs, 
and provide mechanical and biochemical support of the cells (Figure 1.2) by facilitating 
cell adhesion and differentiation. Collagens provide strength and resilience for the highly 
stressed environment and proteoglycans are receptors on cell surfaces. Proteoglycans 
provide cushioning for the cells and glycosaminoglycans are responsible for storage of 
growth factors and cell hydration.11 
 
 
Figure 1.3: Roles of MMPs in physiological processes.12 
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Matrix metalloproteinases (MMPs) are a family of zinc-dependent endoproteases 
produced by cells. MMPs play an important role in ECM turnover by breaking down 
various ECM proteins, such as collagens and elastin.9 They are also vital for tissue 
invasion, immune responses, vascularization, and cell proliferation, migration, and 
differentiation (Figure 1.3). Resident growth factors in the ECM are proteolytically 
cleaved and released by MMPs for cellular uptake.12 Besides degradation of ECM, 
MMPs can degrade cell receptors to terminate migratory signaling and cell migration. 
Within the human body, 23 types of MMPs are known to exist, along with 4 endogenous, 
homologous tissue inhibitors of MMPs (TIMPs). TIMPs are endogenous and bind to 
MMPs at a 1:1 ratio. MMPs are controlled at multiple levels including messenger 
ribonucleic acid (RNA) expression, activation of proenzyme to the active form, and 
binding of TIMPs.12 
1.2.2 The Cells of the Myocardium 
 The myocardium is composed of two main cell types, the cardiomyocytes (CMs) 
and fibroblasts (FBs) (Figure 1.4). Even though CMs occupy the largest volume in the 
heart, around 75%, their populations are only around 30-40%. FBs make up the majority 
of the heart’s population. Smaller populations of vascular smooth muscle cells (SMCs) 
and endothelial cells (ECs) are also found, as they comprise the vascular network in the 
myocardium.13  
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Figure 1.4: Hematoxylin and eosin staining of human myocardium.14 40x; purple=nuclei; 
pink=cytoplasm, tissue.  
 
Figure 1.5:  Cardiomyocyte cross section.7    
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 CMs allow for contraction of the ventricles and atria. Myocytes in the ventricle 
are long and narrow, and can be 10 to 25 um in diameter and 50 to 100 um in length, 
while myocytes in the atrium are oval and are less than 10 um in diameter and around 20 
um in length.15 CMs have one or two nuclei and form Y-shaped branches that join to 
adjacent CMs via intercalated discs (Figure 1.5).7 Intercalated discs allow for force to be 
transmitted from one CM to another, while gap junctions allow for electrical transmission 
between cells.8 Mitochondria account for 60% of the cell volume, providing cellular 
energy through the production of adenosine 5’-triphosphate (ATP) and can also prevent 
intercellular calcium overload through calcium uptake.15  
 
Figure 1.6: Excitation-contraction of a cardiomyocyte.14 
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Contraction of CMs is possible through an intricate network of proteins organized 
in sarcomeres, which are composed of thick and thin filaments (Figure 1.6). Myosin and 
actin comprise thick and thin filaments, respectively. CM contraction is set in motion by 
an action potential that travels along the sarcolemma into the transverse tubule (T-tubule) 
and depolarizes the cell membrane. This in turn opens calcium channels to allow calcium 
in the cell. Intracellular calcium rapidly increases as the sarcoplasmic reticulum releases 
even more calcium in response. Calcium binds to troponin-C on the thin filaments, 
inducing a conformational change and exposing myosin binding sites on the actin 
filament. This binding leads to ATP hydrolysis, which results in a conformational change 
of the actin-myosin complex and a sliding of the filaments, causing the sarcomere to 
shorten. Shortening in this unit is responsible for the overall contraction of the cell. The 
sarcomere length is restored with lowered cytosolic calcium concentration and a ATP 
binding to the myosin head at the end of this cycle.8 
 The structural integrity of the heart relies mainly on FBs, as they are very 
proliferative and produce interstitial collagen for the maintenance of the ECM. They also 
contribute to cardiac development, cell-signaling, and electro-mechanical function. FBs 
are interspersed throughout the myocardium.13 Cardiac FBs are elongated, contain one 
nucleus, and have high cellular activity as they have an intricate endoplasmic reticulum 
and a large Golgi apparatus. FBs are very dynamic in nature and can change phenotypes 
during injury states to become myofibroblasts. Myofibroblasts enhance the inflammatory 
response by secreting cytokines during injury. Cardiac injuries such as ischemia can 
initiate FB phenotypic changes and recruitment to the site of injury, leading to fibrosis16 
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 Blood vessels within the heart supply the myocardium and resident cells with 
oxygen and nutrients. Due to its great energy demands, the myocardium is highly 
vascularized, with an average distance of 12um between capillaries.17 They are 
comprised of FBs, SMCs, and ECs. ECs line the lumen or tunica intima of the vessel, 
forming a non-thrombogenic surface (Figure 1.7) SMCs form the tunica media, the layer 
surrounding the tunica intima, and FBs sheath the outermost layer of the vessel, the 
adventitia or tunica externa. These cells communicate with each other via physical 
contact and soluble or secreted molecules to regulate vessel maintenance, as well as tone 
and blood pressure.18 
 
Figure 1.7: Structure of a blood vessel wall. 
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1.3 Cardiac Disease of the Myocardium 
1.3.1 Coronary Artery Disease and Myocardial Infarction  
 Coronary artery disease is characterized by atherosclerosis in one or both 
coronary arteries, which are the main vessels that supply the myocardium with oxygen 
and nutrients. This can lead to ischemia of the myocardium, myocardial infarction, and 
even sudden death.3 As atherosclerotic plaque ruptures within the artery due to 
inflammatory mechanisms; a thrombus forms and occludes the vessel. Necrosis of the 
tissue supplied by this vessel quickly occurs, followed by inflammation. As mentioned 
before, FBs are very dynamic and during an injury state become myofibroblasts. After a 
MI, macrophages in the infarcted region secrete transforming growth factor-beta (TGF-
β), which guides FBs to myofibroblasts. Myofibroblasts remodel the infarcted tissue by 
secreting collagen I and III, creating a fibrous patch.19  
 
FIGURE 1.8: Illustration of ventricular CM hypertrophy compensation after MI and ischemia of 
the myocardium, leading to irreversible dilation followed by heart failure.20 
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After myofibroblasts remodel the infarct area, the overall mechanics of the heart 
are altered. CMs become hypertrophied to compensate for the lost CMs and maintain 
original cardiac output (FIGURE 1.8).20 This compensation works short term, however 
over time CM hypertrophy and fibrosis of the ECM, lead to enlargement of the heart or 
dilation, and may end in heart failure.21 
1.3.2 Cardiomyopathies 
 Cardiomyopathy is defined as a disease of the heart muscle, mainly of the left 
ventricle. It is marked by decreased systolic and/or diastolic function of the heart, which 
leads to heart failure. Main classifications of cardiomyopathy include; dilated, 
hypertrophic, and restrictive (Figure 1.9), and arrhythmogenic, without noticeable heart 
size or shape change.22  
 
Figure 1.9: Gross morphological changes associated with dilated, hypertrophic, and restrictive 
cardiomyopathies. Dilated cardiomyopathy is marked by ballooning; hypertrophic by noticeably 
thickened walls; and restrictive by stiffened walls.23  
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Dilated cardiomyopathy is defined as ventricular chamber dilation and systolic 
dysfunction with normal ventricular thickness in the absence of abnormal loading 
conditions, such as hypertension.24 It has an estimated prevalence of up to 1:250 and 30-
50% of cases are genetic in nature.25–28 Some cases are idiopathic and other causes 
include myocardial infections, systemic disorders, drugs and toxins, and endocrine and 
metabolic disorders.29–31 Clinical presentations include cardiac arrhythmias, heart failure, 
and in some cases sudden death.32 Hallmarks of this cardiomyopathy include an increase 
in ventricular mass, affecting mainly the left ventricle, a ballooning of the heart into a 
spherical shape, and floppy myocardium.  There is loss of a proper apex leading to 
altered blood flow mechanics and a reduced ejection fraction, which can lead to mural 
thrombi.30,33 At the microscopic level, interstitial and perivascular fibrosis is present in 
the myocardium and the endocardium.32 CMs are the most affected, with myofibril loss 
and varying morphological changes. Many CMs undergo apoptosis which results in a 
mixture of hypertrophic CMs with enlarged nuclei and thin, lengthened CMs in the 
myocardium.34 
Hypertrophic cardiomyopathy is defined as the presence of increased 
ventricular wall thickness or mass in the absence of any loading conditions sufficient to 
cause observed abnormality.33 It has a prevalence of 1:500 worldwide.35 The etiology is 
genetic, with sarcomeric hypertrophic cardiomyopathy being the most common, followed 
by mitochondrial disorders and metabolic or storage disease.36,37 Genetic screening is 
important for diagnosis, as myocardial hypertrophy precedes symptoms and the disease 
can remain stable and under the radar.38 Clinical presentations include left ventricular 
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dysfunction, heart failure, and sudden death.39,40 In this form of cardiomyopathy, the 
myocardium is thick, ranging from mild, 13-15mm, to massive, 30mm.33 Focal 
hypertrophy is found throughout the myocardium, mainly focused on the basal anterior 
septum and anterolateral free wall, which can lead in extreme cases to myocardial 
bridging. The mitral valve is often affected with enlarged leaflets, hypertrophied and 
abnormally positioned papillary muscles, and short chordae, which can lead to subaortic 
obstruction.40 Microscopically in the myocardium there is an overall spatial 
disorganization of myofibers and single CMs, with replacement and interstitial 
fibrosis.35,37 Morphologically, CMs have increased y-branching and side-to-side 
junctions, a whorled appearance, and herringbone pattern. CMs also have decreased 
distribution of desmin, intercalated disks, and z-bands.33 Vascular cells are also affected, 
smooth muscle cells become hypertrophied and intimal thickening and perivascular 
fibrosis are present.35  
 Restrictive cardiomyopathy is defined as reduced diastolic relaxation of the left 
or both ventricles that can occur from many different pathologies. Diastolic filling is 
inhibited with an increase in ventricular filling pressure, while systolic function remains 
unchanged.41,42 Causes are wide ranging and can be isolated or systemic in nature, as well 
as idiopathic. Amyloidosis, sarcoidosis, scleroderma, storage disease, toxicity, 
postirradiation therapy, and genetic mutations are some known causes.42,43 Clinical 
presentations include diastolic dysfunction and heart failure. Biatrial enlargement occurs 
with unchanged atrial-ventricular valves and left ventricular wall thickness. Volume of 
the ventricles can remain unchanged or be decreased. Due to the ranging pathologies 
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leading to restrictive cardiomyopathy, macro and micro changes can vary, depending on 
the cause. For example, in sarcomeric restrictive cardiomyopathy, the atria are 
disproportionately dilated compared to normal ventricular size, while in amyloidosis, the 
atria are only mildly enlarged and the left ventricular wall can be affected in some 
cases.41 Microscopically, interstitial fibrosis of myofibers and CMs are found in 
sarcomeric restrictive cardiomyopathy, while CMs in amyloidosis are atrophic. Amyloid 
deposits are the hallmark of amyloidosis and can be found histologically in the 
myocardium, endocardium, valves, arteries and veins.33 
Arrhythmogenic cardiomyopathy is rare and defined as a genetic heart disease 
mainly affecting the right ventricle. It is a progressive myocardial injury where CMs are 
replaced by fibroadipose tissue.44,45 Worldwide it is estimated to have prevalence up to 
1:2000.46 Mainly desmosomal proteins of intercalated disks are mutated, such as 
armadillo proteins plakiglobin (JUP) and desmocollin-2 (DSC2), however other proteins, 
such as TGF-β3 and desmin can be affected.46,47 Clinical manifestations include 
ventricular arrhythmias, heart failure and an increase in sudden death, especially in 
juveniles and athletes.44,48 With this cardiomyopathy there is no noticeable heart size or 
shape change. The external two-thirds of the right ventricle is normally effaced, and in 
some cases the left ventricle can be as well. The pulmonary infundibulum and outer right 
ventricle wall are the areas most affected.33 In this disease, a mixture of atrophic and 
hypertrophic CMs with vacuolar degeneration are found in the myocardium, separated by 
interstitial fibrosis. CMs are lost and replaced by fibrous or fibroadipose tissue.47 
Lymphocytes and macrophages can also be found in the diseased myocardium.33  
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1.3.3 Diagnosis and Treatments  
 Coronary artery disease and cardiomyopathy are often diagnosed via symptoms or 
physical examination. They are verified through echocardiograms, electrocardiograms, 
cardiac angiograms, cardiac magnetic resonance imaging (MRI), cardiac positron 
emission tomography (PET), and occasionally an endomyocardial biopsy.22 Symptoms 
include fatigue, weakness, shortness of breath, palpitations, light headedness, fainting, 
and chest pain. Treatments can include lifestyle changes such as diet and exercise and 
drugs, including but not limited to, blood thinners, angiotensin converting enzyme (ACE) 
inhibitors, diuretics, corticosteroids, aldosterone, angiotensin II, beta, or calcium channel 
blockers.3 When a myocardial infarction occurs, speedy reperfusion is critical in limiting 
infarct size and percutaneous coronary intervention with balloon angioplasty with or 
without a stent is often utilized to reopen the occluded vessel. Coronary artery bypass is 
another treatment method to supply blood to the ischemic tissue.21 Pacemakers, 
implanted cardioverter defibrillators, and left ventricular assist devices may be utilized 
depending on the severity.3 Unfortunately, these treatments will only slow the 
progression of these diseases and they will ultimately lead to heart failure where the only 
treatment is whole heat transplantation. 
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Figure 1.10: Diagram highlighting alterations in the myocardium caused by a diabetic 
environment that lead to DCMP. 
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1.4 Diabetic Cardiomyopathy 
Diabetic cardiomyopathy (DCMP) is defined as a ventricular dysfunction that 
occurs in diabetic patients independent of coronary artery disease, hypertension, or 
valvular abnormalities.49,50 Metabolic alterations caused by high glucose and 
dyslipidemia contribute to the onset and progression of DCMP (Figure 1.10). Within the 
ventricle, especially the left, fibrosis and microvascular disease changes the normal 
structure and function of myocardium. Normal cellular function is changed by a 
metabolism shift, leading to lipid peroxidation and the buildup of reactive oxygen species 
(ROS), which cause apoptosis and autophagy.50 Diabetic patients have higher instances 
of coronary artery disease, as well as hypertension and atherosclerosis, due to this 
hyperglycemic and hyperlipidemic milieu.3 
1.4.1 Diabetes Mellitus 
 Normally, the body regulates blood glucose levels via a feedback loop to either 
release insulin or glucagon, to maintain homeostasis. During high glucose levels, islet of 
Langerhans beta cells in the pancreas (Figure 1.11) release insulin (Figure 1.12). Insulin 
binds to tyrosine kinase insulin receptors on target cells, inserting glucose transporters 
(GLUT4) on the cell surface for glucose transport (Figure 1.13). The liver then converts 
excess glucose to glycogen for storage and other cells begin to take up glucose via 
GLUT4. During low glucose levels, islet alpha cells release glucagon, which signals the 
liver to convert glycogen to glucose and release it into the blood (Figure 1.14). However, 
this homeostasis is disrupted with the metabolic disease diabetes, leading to not only 
prolonged hyperglycemia, but also a plethora of health issues.51  
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Figure 1.11: Anatomy of the pancreas and islet cells.7 
There are two main types of diabetes. Type 1 diabetes is known as insulin 
dependent diabetes or juvenile onset diabetes. It is characterized by destruction of beta 
cells in the pancreas. This can occur due to an autoimmune disorder triggered by genetic 
or environmental factors. Some cases of type 1 diabetes are idiopathic. Type 2 diabetes is 
known as insulin resistant diabetes and is characterized by a decrease insulin secretion 
and synthesis. Type 2 diabetes is the most prevalent, accounting for 90% of diabetes. 
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This is due to the rise in the epidemic of obesity, especially in developing countries. 
Distribution of abdominal fat in obese type 2 diabetic patients, leads to alterations in cell 
receptors accompanied by resistance to endogenous insulin.51,52  
Treatment of both types focus on control of blood glucose, as mismanagement of 
blood glucose levels by the patient lead to health problems, such as cardiovascular 
disease, and in extreme mismanagement cases, death.3 Type 1 diabetes is treated with 
insulin therapy, accompanied by close monitoring of blood glucose levels with 
glucometers to determine insulin dosage, either through a pump or syringe. Blood 
glucose is also monitored in type 2 diabetes, however due to the nature of this type, 
lifestyle changes, such as healthy eating habits and exercise can be used to treat and even 
reverse this type.53 Unlike type 1 diabetes, there is a wide spectrum associated with this 
type. When lifestyle changes are not enough, oral drugs such as metformin, 
sulfonylureas, thiazolindinediones (TZD), glucagon-like peptide 1 (GLP-1), and 
dipeptidyl peptidase inhibitors (DPP-4) may be used, and in extreme cases, insulin. 
Metformin increases insulin sensitivity and glucose uptake, while decreasing glucose gut 
absorption and hepatic gluconeogenesis. Sulfonylureas raise insulin release in beta cells. 
TZDs are peroxisome proliferator-activated receptor gamma agonists that improve 
insulin sensitivity, lipid profile, and blood glucose control. GLP-1 activates GLP-1 
receptors, which boosts glucose-dependent insulin secretion and decreases glucagon 
secretion. DPP-4 or gliptins raise incretin levels (GLP-1), which has the same outcome as 
GLP-1 treatments.54 
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Figure 1.12: Glucose regulation of insulin secretion in pancreatic beta cells.55 
 
Figure 1.13: Translocation of GLUT4 to the target cell’s membrane via tyrosine kinase insulin 
receptor binding to insulin for cellular glucose uptake.55 
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Figure 1.14: Blood glucose homeostasis.56 
1.4.2 Clinical Diagnosis and Treatment of Diabetic Cardiomyopathy 
 Diagnosis of DCMP is the same as any cardiomyopathy described earlier, and as 
of now is unable to be diagnosed in asymptomatic patients.57 Currently the only 
serological biomarker that can be used is brain natriuretic peptide, however it is a marker 
associated with several cardiac diseases.58 Studies are ongoing to determine biomarkers, 
specifically microRNAs, that could be useful for DCMP diagnosis.59,60 
 Once patients are diagnosed with DCMP, emphasis is placed on glucose control 
and cardiomyopathy treatments are prescribed based on the individual.61 For glucose 
control, type 1 diabetic patients continue with insulin therapy, while extra precautions are 
taken with management prescriptions for type 2 diabetics.62 Sulfonylureas are often not 
prescribed as they may not function, due to heart failure being an insulin resistant state.3 
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TZDs increase fluid retention, so they are cautioned for use with class I and II heart 
failure and not recommended for use with class III and IV heart failure by the New York 
Heart Association (Table 1.1).58 DCMP can be treated with, but not limited to, lifestyle 
changes, ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, beta 
blockers, calcium channel blockers and diuretics.63,64 Depending on the severity and the 
symptoms, combinations of these can be used.65 Calcium channel blockers are not 
recommended for heart failure patients with type 1 diabetes.3 As the DCMP worsens, 
depending on the progression and individual, devices such as implantable cardioverter 
defibrillators, cardiac resynchronization devices, left ventricular assist devices, and even 
whole heart transplants may be employed. However, surgeries are risky, and one of the 
many criteria is that the patient have established glycemic control.3 Unfortunately, there 
is no cure for DCMP, like other cardiomyopathies.  
Class I Cardiac disease, but no symptoms and no limitations in normal physical activity
Class II Mild symptoms and slight limitation during ordinary activity
Class III Significant limitation in activity due to symptoms- comfortable only at rest
Class IV Severe limitations- symptoms even while at rest
New York Heart Association Classifications of Heart Failure
 
Table 1.1: Classifications of heart failure from the New York Heart Association.66 
 Understanding of the progression of DCMP can be broken down into three stages. 
Molecular and cellular events from hyperglycemia and dyslipidemia cause structural 
alterations that lead to myocardial dysfunction and heart failure (Table 1.2).3,65 However, 
this is a general understanding of the occurrence of this disease and as new knowledge of 
DCMP is brought to light, the progression and alterations may not be this rigid. Clinical 
findings hint at the possibility of two phenotypes associated with either type 1 diabetes or 
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type 2 diabetes, which are dilated cardiomyopathy with reduced left ventricular ejection 
fraction and restrictive cardiomyopathy with preserved left ventricular ejection fraction, 
respectively.67 
 
Table 1.2: General progression of DCMP highlighted by three stages.3 
1.4.3 Metabolic Shift in Diabetes  
As mentioned before, left ventricular CMs have very high-energy demands. 
Within the human body, the heart utilizes the largest amount of energy per gram of tissue, 
roughly 20 times its own weight per day.68 Approximately 70 percent ATP produced in 
the resting heart is due to FFA oxidation.68 Uptake of FFAs into the CM is mediated via 
three transporters; cluster of differentiation 36 (CD36), fatty acid transport protein 1, and 
plasma membrane form of fatty acid binding protein. CD36 is stored in intracellular 
vacuoles (~50%) where it can be recruited to the sarcolemma membrane for the uptake of 
FFA under conditions such as muscle contraction, and stimulation by insulin and 
caffeine.68 Physiologically, there is flexibility in the heart, allowing for shifts in the 
utilization of glucose and free fatty acids (FFA). Nutrients increase myocardial insulin 
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signaling and plasma insulin levels within the body. This leads to translocation of 
GLUT4 and CD36 to the CM sarcolemma, for glucose and FFA uptake, respectively, in 
order to supply myocardial energy substrates.57   
 
Figure 1.15: Pathophysiology of diabetes mellitus on energy metabolism in the heart.68 
In the diabetic heart, this plasticity is lost, due to increased FFA in the circulation 
and depletion of GLUT4 (Figure 1.15).69 High FFA levels activate transcription factor 
peroxisome proliferator-activated receptor alpha (PPARα) in the CM nucleus, leading to 
increased myocardial FFA oxidation and utilization via upregulation of CD36 expression, 
thus upregulating mitochondrial fatty acid beta-oxidation.70 Insulin signaling is 
suppressed as insulin receptor substrate 1 (IRS1) is inhibited from accumulation of FFA 
and their derivatives.68 CD36 is highly expressed on the sarcolemma, while GLUT4 
returns to its intracellular location.71 In this unbalanced environment, mitochondrial 
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oxidation capacity is exceeded and mitochondrial fission is increased, resulting in 
mitochondrial fragmentation with an accumulation of ROS, which can lead to 
apoptosis.72,73 Increased circulating FFA also lead to inhibition of pyruvate 
dehydrogenase through pyruvate dehydrogenase kinase 4 (PDK4), impairing glycolysis 
and causing the buildup of glycolytic intermediates and intracellular lipids, such as 
ceramides.74 This lipid accumulation decreases contractile function, hinders physiological 
autophagy, and impairs insulin signaling, leading to increased apoptosis within the 
myocardium.58 These metabolic alterations ultimately lead to ROS production, 
lipotoxicity, CM death and hypertrophy, altered calcium handling and myocardial 
fibrosis.57 
1.4.4 Oxidative Stress 
Within the healthy cardiovascular system, a balance exists between ROS 
production and their removal by antioxidants.75 Production of ROS is a naturally 
occurring process within the body and sources of ROS arise from non-enzymatic, 
enzymatic, and mitochondrial reactions.76 Non-enzymatic formation of ROS occurs via 
autoxidation of glucose as well as a reaction between protein and glucose (Figure 
1.19).64,77 Sources of enzymatic formation of ROS are nitric oxide synthase (NOS), 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, and xanthine oxidase.64 
The mitochondrial respiratory chain also provides a source of ROS, during oxidation 
phosphorylation.78 In the physiological state, ROS play an important role in cell 
signaling, biosynthesis, and is an anti-infectious defense and a balance exists between 
ROS formation and antioxidant defense mechanisms.79 Enzymatic and non-enzymatic 
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defense mechanisms in the body eliminate ROS. Enzymatic mechanisms such as 
superoxide dismutase (SOD) and glutathione reductase are important in removal of 
ROS.80 Non-enzymatic antioxidants include glutathione, coenzyme Q10, and vitamins A, 
E, and C.76 This balance is important, as elevated ROS leads to oxidative stress, a 
harmful state which can alter cellular function and lead to cell death.49  
As mentioned before, the loss of metabolic plasticity in the diabetic heart leads to 
increased FFA oxidation in CM mitochondria followed by ROS accumulation. Due to 
high energy demands of CM, it is theorized that the mitochondria are responsible for the 
majority of ROS production in this diseased state.81 This influx of ROS supersedes 
endogenous antioxidant defense mechanisms, leading to oxidative stress.82 Constant 
oxidative stress degenerates proteins, deoxyribonucleic acid (DNA), and lipids within the 
cells (Figure 1.16) causing cellular dysfunction that leads to apoptosis and autophagy.83 
 
Figure 1.16: Schematic of pathologic outcomes of mitochondrial ROS production and prolonged 
oxidative stress due to hyperglycemia and hyperlipidemia.84  
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1.4.5 Impaired Cardiomyocyte Contraction 
Intracellular calcium in the CM is responsible for excitation-contraction coupling 
during cellular contraction at the micro-scale and myocardial compression at the macro-
level.85 Calcium enters the cell through L-type calcium ion channels (ICa-L), which 
activates calcium release from endoplasmic reticulum and sarcoplasmic reticulum via 
ryanodine receptors (RyRs), leading to increases of calcium that binds to troponin C, 
activating contraction. Relaxation of CMs occurs through the release of calcium from 
troponin C, followed by calcium uptake via sarcoplasmic/endoplasmic reticulum Ca+2-
ATPase (SERCA), Na+2/Ca+2 exchanger (NCX), sarcolemmal Ca+2-ATPase, and 
mitochondrial Ca+2 ATP uniport.86 
In the diabetic environment, dysfunctional intracellular calcium signaling and 
lower expressions of ion channels, SERCA, NCX, RyRs, and decreased myofilament 
calcium sensitivity in CMs lead to an imbalance in calcium homeostasis (Figure 1.17).87 
Hyperglycemia upregulates protein kinase C (PKC) and downregulates protein kinase A 
(PKA), which causes depression of outward potassium currents (Ito) and ICa-L and L-type 
calcium channel expression.88 High glucose also increases phosphorylated 
phospholamban (PLB) which reduces activity of SERCA and decreases overall SERCA 
and NCX expression.89 Calcium homeostasis is furthermore upset with the dysfunction of 
RyR due to hyperphosphorylation, causing leakage of calcium during diastole and 
depletion of sarcoplasmic reticulum calcium stores.74 Sensitivity of myofibrils to calcium 
are compromised with phosphorylation of troponin I and T from increased PKC 
activation, which leads to slower cross-bridge cycling.90 AGEs produced in high glucose 
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conditions irreversibly bind between calcium handling proteins, such as SERCA and 
RyR, leading to their inactivation.91 Myosin switches from the alpha to beta isoform in 
diabetes slows actin-myosin kinetics and depresses myosin and myofibrillar ATPase 
activity.92 N2B to N2BA titin ratios shift towards N2BA, a more elastic isoform, and titin 
becomes hyperphosphorylated, causing contraction dysfunction.92 Overall, these 
alterations in calcium handling are detrimental to cardiac efficiency and are obvious in 
slowed CM contraction and relaxation, prolonged action potential duration, and reduced 
shuttling of intracellular calcium.87  
 
FIGURE 1.17: Alterations within the cardiomyocyte in diabetic cardiomyopathy that cause 
contraction dysfunction and reduced cardiac efficiency.92  
1.4.6 Endoplasmic Reticulum Stress 
 The endoplasmic reticulum (ER), comprised of rough and smooth regions, is the 
main site for synthesis and processing of proteins and lipids in the secretory pathway. 
Within the closed ER lumen, newly polypeptide chains synthesize, fold and mature.7 
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These posttranslational modifications and folding interactions optimize protein function 
before correctly folded proteins are exported to the Golgi apparatus and transported to 
intracellular organelles or extracellular membrane. The ER also is a storage site for 
calcium.93 Accumulation of unfolded or misfolded protein within the lumen of the ER 
induces ER stress. This mechanism of action is triggered to restore homeostasis and can 
lead to the unfolded protein response (UPR).94 Conditions such as radiation, hypoxia, 
ischemia, oxidation, dysregulation of calcium, altered metabolism, or DNA mutations 
lead to ER stress.95  
 Increased circulated FFAs and hyperglycemia cause a metabolic shift, 
accumulation of ROS, and issues of calcium handling within the CM.96 These in turn lead 
to ER stress and the UPR to control protein quality. There are three main pathways that 
are utilized during the UPR; inositol-requiring enzyme 1 (IRE1), protein kinase RNA-like 
ER kinsase (PERK), and activating transcription factor 6 (ATF6) pathways (Figure 
1.18).97 In the unstressed state, these sensors are bound to binding protein (BiP) and 
remain inactive.98 When misfolded proteins are present in the ER lumen, BiP unbinds 
from IRE1, PERK, and ATF6, allowing it to attach to misfolded proteins to serve as a 
chaperone.99 Misfolded proteins have exposed hydrophobic regions, which BiP readily 
binds to.97 Once IRE1 is activated, it becomes phosphorylated by PKA and splices X-box 
binding protein 1 (XPB1) messenger RNA, yielding transcription factor XBP1s for 
expression of UPR target genes, upregulation of ER chaperones, and exportation and 
degradation of misfolded proteins.100  IRE1 also activates Jun N terminal kinase (JNK) 
which can lead to apoptosis and autophagy.101 After unbinding of BiP, PERK 
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phosphorylation of eukaryotic translation initiation factor 2 alpha (eIF2α) reduces protein 
translation, while increasing activating transcription factor 4 (ATF4), which induces 
transcription of CCAAT/-enhancer-binding protein homologous protein (CHOP). ATF4 
and CHOP upregulate genes involved in protein synthesis and ER associated degradation 
(ERAD).93 PERK also phosphorylates nuclear factor (erythroid-derived 2)-related factor2 
(Nrf2), which turns on genes that combat oxidative stress.102 In the ATF6 signaling 
pathway, unbinding of BiP frees ATF6 from the ER and is translocated to the Golgi 
apparatus, where it is cleaved by resident proteases.97 This cleaved cytoplasmic domain 
activates genes involved in lipid biosynthesis, protein folding, ER expansion, and 
ERAD.103 Under prolonged ER stress, these pathways lead to autophagy and apoptosis.96  
 
Figure 1.18:  Illustration of ER stress and the UPR, leading to the activation of the ATF6, 
IRE1, and PERK pathways in response.101,104  
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1.4.7 Extracellular Matrix Changes  
 During hyperglycemia, an influx of glucose leads to the formation of advanced 
glycation end-products (AGEs), form irreversible cross-links within lipids and proteins, 
such as collagen, laminin, and elastin, and cause fibrosis.105 This cross-link is formed by 
the Maillard reaction via a Schiff base and Amadori product (Figure 1.19). Matrix 
metalloproteinases are unable to degrade these irreversible ECM modifications, causing 
an imbalance in physiological ECM turnover.106 AGE formation can induce cardiac FB 
proliferation and elevated collagen production.107 Accumulation of AGEs lead to vascular 
disease, as when it binds to a receptor for AGEs (RAGE), it increases endothelial 
permeability to macromolecules.108 Oxidative stress upregulates RAGE expression, 
which in turn causes increased NADPH oxidase expression, mitochondrial oxidase 
activation, and suppresses endogenous antioxidant activity.109 This establishes a positive 
feedback loop between ROS formation and RAGE expresssion.106  
Inhibition of matrix metalloproteinase (MMP) activity, macro and microvascular 
disease, and altered AGE and RAGE expression lead to myocardial thickening and 
fibrosis (Figure 1.20).111,112 Fibrosis causes the myocardium to stiffen and vascular 
disease decreases nutrient transport within the myocardium, inducing cell death in this 
vicious cycle.50 As CMs undergo apoptosis and autophagy, the ventricle must continue to 
pump at the same rate, so the surviving CMs must compensate for ones that have died 
off. To do so CMs enlarge and become hypertrophied.113 As they are continually 
overstressed mechanically and as more CMs continue to die in the toxic diabetic 
environment, the myocardium function gradually declines, ending in heart failure. 
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Figure 1.19: Mechanism for AGE formation via glycoxidation.110 
 
 
Figure 1.20: Autopsy of a heart with DCMP. (A) Gross anatomy showing hypertrophy of the left 
ventricle. (B) Hematoxylin and eosin staining showing fibrosis and cardiomyocyte hypertrophy 
within the left ventricle.113   
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1.4.8 Potential Antioxidant Therapies 
Researchers have started focusing on antioxidant therapies to combat elevated 
ROS in within the diabetic environment.114,115 One method of interest is increasing 
intracellular SOD content. This is a favorable countermeasure; however, SOD isoforms 
are very large, making them difficult to permeate the cells, and they have a very short 
half-life. Mito-TEMPO ((2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-oxoethyl) 
triphenylphosphonium chloride) is a mimetic form of SOD, that is more stable and 
smaller, allowing it to overcome these barriers (Figure 1.21).116 Ni et al. tested mito-
TEMPO in type 1 diabetes streptozotocin (STZ) and type 2 diabetes db/db mouse models. 
They found in both animal models that daily injections of mito-TEMPO for 30 days 
inhibited mitochondrial ROS generation, prevented intracellular oxidative stress levels, 
decreased apoptosis, and reduced myocardial hypertrophy in diabetic hearts.78  
 
Figure 1.21: Structure of mito-TEMPO.117 
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Rutin is another appealing antioxidant. It is a citrus flavonoid found in a variety 
of plants (Figure 1.22).118 Bhandary et al. investigated a series of flavonoids in a study to 
determine if all or any would have a protective effect on ischemic/reperfused rat hearts. 
To test different concentrations of flavonoids, harvested rat hearts, subjected them to 
ischemia, reperfused them, and then perfused treatments through them. They found that 
rutin enhanced SOD activity and had consistent protective effects in ischemic/reperfusion 
injury.80 In other studies performed by Saklani et al. and Wang et al. on STZ  induced 
type 1 diabetic rats, rutin treatments significantly protected hearts against diabetic 
oxidative stress, improved electrocardiography parameters, apoptosis, and inflammation 
in the diabetic hearts.118,119 
 
Figure 1.22: Structure of Rutin.120 
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Coenzyme-Q10 is an antioxidant that is endogenously synthesized and is a 
lipophilic cofactor of the mitochondrial electron transport chain (Figure 1.23). It is 
available as a non-prescription oral dietary supplement and has been shown to be 
beneficial when used with other therapies for chronic heart failure.121 Blasio et al. studied 
the effect of coenzyme-Q10 on an exacerbated diabetic cardiomyopathy mouse model 
with reduced phosphoinositide 3-kinase (PI3K) signaling, which upregulates NADPH 
oxidase.  6-week-old dominant negative PI3K p110α mice were treated with STZ and 
after 4 weeks were treated with coenzyme-Q10. Within this aggravated model, coenzyme 
Q10 reduced left ventricular diastolic dysfunction, CM fibrosis and hypertrophy, 
expression of atrial natriuretic peptide, connective tissue growth factor, and β-myosin 
heavy chain.77 
 
Figure 1.23: Reduction of ubiquinone (coenzyme-Q10) to ubiquinol through semiquinone 
intermediate.122 
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There has also been a shift towards naturally occurring plant-based antioxidants, 
such as curcumin, garlic, and broccoli.123 Turmeric powder, with the active polyphenol 
curcumin (Figure 1.24), has been used as a spice for cooking and medicinal purposes in 
Asia for thousands of years.124 Yu et al. treated type 1 diabetic induced STZ rats with oral 
administrations of curcumin and found that it attenuated myocardial dysfunction, cardiac 
fibrosis, AGE accumulation, oxidative stress, apoptosis, and inflammation in the diabetic 
rat hearts.125 Sahebkar et al. performed a meta-analysis of eight randomized controlled 
clinical trials and found curcumin treatments significantly reduced pro-inflammatory 
cytokine tumor necrosis factor alpha (TNFα).126  
 
Figure 1.24: Structure of curcumin.127 
There are many ongoing investigations of other potential antioxidants not only for 
treatment of cardiac disease in diabetes, but also cardiovascular diseases in general, 
cancer, arthritis, autoimmune disorders, phycological diseases, neurological issues, etc.114 
Many of these antioxidants are on the market in non-prescription supplemental forms, 
however additional research into dosage and effect, as well as monitoring of production 
need to be performed. Antioxidants target sources of many diseases, making it a 
promising therapeutic avenue.        
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1.5 Cardiac Tissue Engineering  
 Tissue-engineered models have been used to address discrepancies between 
animals and humans to investigate diseased states. These organotypic models aim to 
replicate specific architecture and relevant physiological function of the tissue for 
analysis.128 This is useful for studying disease progression, as well as drug screening and 
treatment testing. Myocardial tissue engineering combines cells, scaffolds, and cues to 
create a structure and network similar to the native tissue. Many groups are looking to the 
promise of tissue-engineered myocardium, not only for the study of normal and diseased 
myocardium, but also for the hope of creating functional myocardium as a treatment for 
heart disease.129 This overlap has led to the rise of different approaches to develop tissue-
engineered myocardium that have the crossover potential to be used for modeling and 
diseased tissue replacement.  
1.5.1 Cardiac Scaffolds   
 Scaffolds for cardiac tissue engineering are utilized to provide an environment 
comparable to native myocardial ECM for cells to attach and align, interact with each 
other, transmit load, and conduct electric signals. The scaffold must also be able to be 
remodeled by the cells (i.e.- biodegradable) and have similar mechanical properties to 
withstand physiological cyclic strains and stresses.130 It should be biocompatible and 
have porosity that promotes vascularization and diffusion of oxygen and nutrients to 
support the seeded cells.131 
 Biomaterials utilized for cardiac scaffolds include, synthetic, natural, and 
combination. Several natural materials employed include collagen, fibrin, hyaluronic 
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acid, Matrigel, and preparations of native heart matrix. Some synthetic materials applied 
include polyesters such as poly(lactic acid) and poly(glycolic acid), poly(lactones), 
polyurethanes, and polysebasic acid.130 Combinations of synthetic and natural materials 
such as poly(e-caprolactone) and gelatin or collagen have also been used.132 Scaffolds 
can further be categorized by method of fabrication such as hydrogel, prefabricated 
matrices, decellularized tissue, and cell sheets. Advantages and disadvantages that should 
be taken into consideration when deciding on a method to use (Table 1.3).131  
Scaffold Source Advantages Disadvantages
Natural, Synthetic and Mixed In-situ injection of cells Fragile, prone to breakage
Lessened immune response
Natural, Synthetic and Mixed Easy to engineer and manipulate 3D forms Optimal porosity needs to be maintained 
Exact ECM structure difficult to create
Natural Vascularization Difficulties reseeding
Immune response eliminated
Native ECM protiens retained
Natural Easy to scale up in 3D form Fragile and difficult to handle
Easy to manipulate Limited thickness
Decellularized
Cell Sheets
Hydrogels
Prefabricated
 
Table 1.3: Types of scaffold fabrication methods with materials that can be used and some 
advantages and disadvantages of each.131  
 Hydrogels are produced by crosslinking water-soluble polymers. They can be 
made from natural or synthetic materials or combinations. Cells can integrate and grow in 
the scaffold.131 To increase cell anchoring and integration, growth factors and peptides, 
such as arginylglycylaspartic acid (RGD) for cell adhesion. Hydrogels are favorable 
vehicles for cardiac cell and/or growth factor in-situ injection, as it can increase delivery 
efficiency via protective encapsulation and catheters can be used for transport, 
eliminating the need for invasive surgery and use of drugs or anesthesia.131 Encapsulation 
by hydrogels can also alleviate immunogenic responses post implantation. For cardiac 
applications, this scaffold type is limited by its ability to withstand physiological forces 
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seen in the heart.133 Wang et al. injected crosslinker tetraaniline-polyethylene glycol 
diacrylate and thiolated hyaluronic acid, along with adipose derived stem cells and 
plasmid DNA encoding endothelial nitric oxide synthases (eNOs) nanocomplexes into 
the myocardium of rat infarct models. In rats there was an increase in ejection fraction, 
shortened QRS interval, smaller infarction size, less fibrosis, and higher vessel density 
within the hearts.134 Tang et al. injected human cardiac stem cells in thermosensitive 
poly(N-isopropylacrylamineco-acrylic acid) nanogel into mouse and pig myocardial 
infarction models. In mice and pigs treated with cells and hydrogels, cardiac function was 
preserved and scar size was decreased.135  
Prefabricated matrices are useful for cardiac tissue engineering, as mechanical 
properties, behavior, porosity, size, and degradability are tailorable.131 These scaffolds 
can be made from natural, synthetic, or combination materials. Pores of these scaffolds 
can be tailored by methods such as, porogen leaching, freeze drying, phase separation, 
and electro-spinning. Difficulties can arise in using preformed matrices, as it is difficult 
to exactly recapitulate ECM and overall organ structure with this method.131 Gu et al. 
fabricated cardiac patches with electro spun elastomeric polyester urethane urea and 
polyester ether urethane urea with incorporated recombinant adeno-associated virus- 
green fluorescent protein (GFP) labelled- to test addition and release of viral vectors in 
infarcted rat models. GFP was expressed even after 12 weeks and mechanical support 
provided by the scaffold improved remodeling and provided support to the compromised 
infarct tissue.136 Tsui et al. constructed cardiac scaffolds from electroconductive-acid 
modified silk fibroin-poly(pyrrole) substrates patterned with nanoscale ridges and 
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topography similar to native ECM. Human induced pluripotent stem cell (iPSC) 
cardiomyocytes were cultured on this material for 21 days and showed increased cellular 
organization and sarcomere development, with increased connexin-43 expression.137 
Tissue decellularization (decell) is a method that uses the organ itself to provide 
the 3D structure of interest through detergent washes to remove cells and cellular 
material, leaving the ECM and vasculature intact. Decelling is a favorable method, as 
immunogenic material is removed and native ECM, such as collagen, elastin, and 
laminin, is retained, allowing for patient specific cells to be integrated into the native 
scaffold to create an individually tailored tissue.138 One obstacle to overcome with this 
scaffold is homogenous cell seeding. Perea-Gil et al. tested decellularized porcine 
myocardium and human pericardium that were reseeded with or without porcine adipose 
mesenchymal stem cells in porcine myocardial infarct models. Both scaffolds with or 
without cells restored function of myocardium post infarction and integrated with the 
underlying tissue via neovascularization.139 Decell is based on the idea that nature is the 
best engineer. Recently, other vascularized things in nature, such as plants, have been 
researched. Gershlak et al. decellularized spinach and parsley leaves and roots were 
performed and seeded with human cells. Human iPSC cardiomyocytes seeded showed 
contractile function and calcium handling capabilities over the course of 21 days.140  
Cell sheets are considered a scaffold free approach and are employed to 
overcome the obstacle of low cell concentrations and inflammatory reactions of scaffolds. 
They are fabricated by culturing cells on poly-N-isopropylacrylamide, a temperature 
sensitive polymer, until they are confluent.141 At 37 degrees Celsius, the cell culture 
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dishes are hydrophobic and cell adhesive. The monolayer of cells can be detached from 
the polymer at 32 degrees Celsius, leaving the ECM and proteins intact. These fragile 
sheets can then be layered to a maximum thickness of 80um to form tissue.131 Shudo et 
al. implanted a bilayered cell sheet of rat endothelial progenitor cells (EPCs) and rat 
mesenchymal stem cells differentiated into smooth muscle cells (SMCs) into a rat model 
of ischemic cardiomyopathy. Rats treated with the EPC-SMC cell sheet had increased 
mature vessel density, decreased cardiac fibrosis, increased left ventricular ejection 
fraction, and decreased left ventricular dimensions.142 Sakaguchi et al. fabricated 10um 
thick cell sheets with neonatal rat CMs at 30 degrees Celsius in order to slow metabolism 
and allow for myocardial tissue formation and prevascularization. Lower temperature 
cultured cell sheets were implanted under the skin of nude rats and developed denser 
prevascular networks compared to cell sheets cultured in normal conditions, showing 
promise for cardiac applications.143 
1.5.2 Cardiac Cell Sources 
 To develop functional myocardium for cardiac tissue engineering applications, 
there are several cell sources for consideration. Some sources are acceptable for 
implantation, while others are only suitable for disease modeling and screening for 
individual patient therapies. Allogenic sources include CMs, embryonic stem cells 
(ESCs), cardiac progenitor cells (CPCs), and cardiac stem cells (CSCs). Autologous 
sources include adipose derived stem cells (ADSCs), skeletal myoblasts, bone marrow 
derived stem cells (BMDSCs), and iPSCs (FIGURE 1.25).131 Allogenic sources have 
been investigated, however complications arise with activation of the immune response. 
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CPCs and CSCs are difficult to source, as they are estimated to make up 1% of total cells 
in the heart. It is also problematic acquiring CMs from healthy hearts, as they will be 
used for whole organ transplantation.132 There are ethical concerns with ESCs and when 
transplanted in vivo, tumors can form and they may induce arrhythmias.144 
 
FIGURE 1.25: Diagram of potential allogenic and autologous cell sources for cardiac tissue 
engineering.131 
 Autologous skeletal myoblasts have been investigated for transplantation 
treatments of diseased myocardium, as they are easy to isolate, resistant to ischemia and 
fatigue. However, with skeletal myoblast transplantation there is an increased risk of 
arrhythmias as they fail to structurally integrate into the myocardium and beat 
independently of neighboring CMs.144 BMDSCs are another potential source from which 
mesenchymal stem cells (MSCs) and EPCs can be isolated from. MSCs are easy to 
isolate, can differentiate into CM-like cells in vivo and in vitro, however they have a low 
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differentiation efficiency.145 They have been shown to improve left ventricular ejection 
fractions in animal myocardial infarction models when directly injected into infarct or 
when administered intravenously.146 EPCs have been shown to increase 
neovascularization and cardiac function in infarct models, though low numbers limit their 
use.147 iPSCs can be derived from adult cells, however this is a long, costly process, with 
low efficiency of 0.01-0.1 percent.132 Problems arise with the use of iPSCs in vivo, as 
there are concerns with tumor formation and iPSCs differentiated into CMs from patients 
with cardiomyopathy have been shown to retain diseased phenotypes.148  ADSCs are easy 
to isolate and are widely available within the body. In preclinical studies, they have been 
shown to decrease infarct size and survival. In the PRECISE trial in Europe ADSC 
treated patients with ischemic cardiomyopathy had a reduction in inducible ischemia and 
improvement in peak oxygen consumption at 18 months.149  
1.5.3 Cardiac Bioreactors  
 Merging scaffolds and cells with a bioreactor, certain conditions can be met to 
produce a more physiologically relevant environment to precondition myocardial-like 
tissue prior to implantation or create models for the study of disease states. 
Preconditioning increases cell functionality, as well as guides cells towards myocardial 
cell lineages such as CMs.150 Physiological myocardial environment recapitulation in a 
bioreactor requires addition of elements such as, perfusion, electrical stimuli, and 
mechanical loading, which can be added to necessary controlled conditions such as pH, 
temperature, and nutrients.129,151 If the thickness of the myocardial-like tissue is greater 
than ~150um, perfusion is necessary for oxygen diffusion.17 
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 It has been established that electrical stimulation affects cell alignment, 
differentiation, metabolic activity, protein synthesis, connexin 43 expression, conduction 
velocity, calcium handling, and force generation.150 Physiological electrical properties 
such as rectangular shape and 2ms duration at 5V/cm and 1Hz are successful in inducing 
these changes.152  Radisic et al. cultured neonatal rat CMs on collagen sponges and 
subjected them to an electrical stimulus (2 ms, 5 V/cm, 1 Hz), comparable to native 
myocardium for 5 days utilizing carbon rods. Cells were aligned and coupled; 
intercalated discs, gap junctions, myofibrils, and T-tubules formed; and important 
proteins such as troponin I, α-actinin, connexin 43, α- and β-myosin heavy chain 
increased.153 
 Mechanical strain is also important for CM alignment and maturation. 
Zimmerman et al. mechanically loaded (cyclic stretch at 10%, 2 Hz) neonatal rat CMs 
seeded on collagen I scaffolds for 7 days and found that CMs more closely resembled 
adult myocardial tissue when compared to 6-day old native neonatal rat myocardium. 
They observed morphological changes such as a basement membrane, well developed T-
tubules, cell alignment along the construct and increases in myofilaments, sarcomeric 
organization, gap junctions, desmosomes, adherens junctions.154 
 Electrical and mechanical stimuli combined improve CM functional properties 
over electrical or mechanical stimulation alone. Morgan and Black subjected neonatal rat 
CMs in fibrin gel on latex tubing to electrical (rectangular pulse, 1ms, 3V/cm, 1Hz) and 
mechanical (5% stretch, 50% duty cycle, 1Hz) stimulation in an electromechanical 
bioreactor they constructed (Figure 1.26) for 14 days. They found that combined 
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electromechanical stimuli enhanced myocardial-like tissue function by increasing 
expression of SERCA2a, troponin T, protein kinase B (Akt), proteins responsible for cell-
cell communication and contractility.155 
 
Figure 1.26: Electromechanical bioreactor produced in the Black Laboratory.155  
1.5.4 Current Diabetic In Vivo and In Vitro Cardiac Models 
Animal models are currently used to understand early cardiac alterations in 
diabetes and heart failure, while cadaveric hearts have been used to study end stages heart 
failure in diabetic patients. Animal models are useful, however there are many 
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physiological discrepancies between humans and animal models.156 Rodent models, 
particularly rat and mouse, are the typical choice for diabetic cardiac research, as they are 
relatively inexpensive, easy to house and care for.156 Mouse models are employed as they 
are easy to manipulate genetically.74 Type 1 diabetic rodent models such as the 
streptozotocin (STZ) induced diabetes in rat or mouse model, OVE26 mouse, and Akita 
diabetic mouse are common for cardiac diabetes studies.156 Standard type 2 diabetes 
models include the Zucker diabetic fatty rat (ZDF), db/db mouse, and ob/ob mouse.6 
While these models have been helpful in determining alterations that could be occurring 
in diabetic myocardium, and have been widely accepted, there are major discrepancies 
between humans and the rodent models. Rodents have a higher heart rate, differing 
electrophysiological properties of CMs, and varying circulating lipid concentrations when 
compared to humans.6 One of the major discrepancies often overlooked for rodent 
models are differences in the immune response when compared to humans. Diabetes is a 
prolonged inflammatory disease.65 Taking into consideration marked differences seen 
among host immune responses in human patients and rodent subcutaneous implants, there 
most assuredly are differences between rodent models and patients in this extended 
inflammatory disease.157 Inconsistencies also exist in the progression of cardiac 
alterations in these diabetic rodent models and within the models themselves. Depending 
on the lineage of the rodent, genetic manipulation, and severity of obesity and diabetes, 
some models are more susceptible to changes and show a rapid progression of diabetes 
and heart failure.6 For example, when comparing type 2 diabetic models, cardiac 
efficiency is markedly lower for db/db and ob/ob mice, but does not change for ZDF 
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rats.158–160 In the Akita type 1 diabetic model it has been shown depending on the study 
that cardiac size can remain the same or increase.161,162 Disparities may arise depending 
on the sex of the animal. Akita male mice are usually more favorable for diabetes 
research as female Akita mice have less pronounced hyperglycemia when compared to 
their male counterparts.163 
 In vitro models have been employed to study cardiac alterations in diabetes and 
changes that occur in specific cell types, however their models have either lacked a 
dynamic 3D environment with an ECM or utilized animal cells instead of human 
cells.148,164 Song et al. statically cultured rat neonatal cardiomyocytes on collagen 
scaffolds in either low (1g/L) or high (4.5g/L) glucose with or without insulin (20µM) for 
8 days. They saw poor electric properties and an increased ratio of myosin heavy chain 
isoform β to α in high glucose cultures.164 Drawnel et al. cultured human iPSC derived 
cardiomyocytes, from two type 2 diabetic patients and a non-diabetic patient and 
subjected them for two days to either a manufacturer’s maintenance medium without 
glucose or a “diabetic” medium with glucose (10mM), as well as endothelin-1 (10nM) 
and cortisol (1µM) to dull insulin sensitivity. iPSC-CMs from type 2 diabetic patients 
showed baseline cardiomyopathy (CM hypertrophy, loss of sarcomeric integrity) without 
being cultured in “diabetic” medium and normal iPSC-CMs cultured in “diabetic” 
medium showed baseline cardiomyopathy as well.148 
1.6 Conclusions 
 The risk for cardiac disease is dramatically increased in diabetic patients. This is 
due to the diabetic environment, as hyperglycemia and dyslipidemia cause metabolic 
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disturbances that adversely affect myocardial cells and ECM. These modifications 
aggregate to alter overall myocardial structure and cardiac function, leading to DCMP. 
As of now there is no specific marker for this disease and diagnosis is the same as other 
cardiomyopathies. Elucidating early stages of this disease is vital for determining markers 
for early diagnosis, treatment, and possible therapy targets. As of now, animal models 
and 2D studies have been utilized to understand early changes associated with DCMP, 
however there are discrepancies with animal models and 2D studies fail to recapitulate 
the ECM and dynamic environment. Tissue engineering is vital in bridging this gap. By 
combining scaffolds, cells, and biochemical and physical stimuli, we can elucidate early 
alterations in DCMP, as well as test potential therapies for treatment. 
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CHAPTER 2: RESEARCH MOTIVATION, SPECIFIC AIMS AND PROJECT 
SIGNIFICANCE 
 
2.1 Introduction 
As diabetes mellitus rises to epidemic proportions across the world, so follows 
an upsurge in the number of patients who have heightened risk of cardiovascular disease. 
The risk of cardiovascular disease, such as hypertension, diabetic cardiomyopathy, and 
atherosclerosis are increased in diabetic patients.1,2 Diabetic cardiomyopathy (DCMP) 
is a ventricular dysfunction that specifically occurs in diabetic patients independent of 
coronary artery disease, hypertension or valvular abnormalities.3  
Heart transplantation is the only cure for DCMP, which has a very long wait list.4 
Treatment is lumped in with other cardiomyopathies and heart failure, however these 
therapies only treat the symptoms and downstream complications that accompany heart 
failure without addressing the roots of the problem.5 Understanding the fundamental 
mechanisms in the early stages of DCMP are vital for early diagnosis and targeted 
therapies. As of now, comprehension of this disease has depended on rodent models, cell 
culture models, and cadaveric human patient hearts.6,7  Human DCMP cadaveric hearts 
have been useful for elucidating end stage cellular and extracellular changes and rodent 
and cell culture models have been utilized to fill in the gaps. However there are many 
discrepancies that exist between humans and rodents.8–10 Human cells have been 
employed to examine specific cell type alterations associated with the diabetic 
environment, but this is in an oversimplified 2D static environment, lacking an 
extracellular matrix (ECM).11 
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Our long-term goal is to develop a tissue engineering platform to investigate 
mechanisms of early cellular and extracellular alterations of DCMP. To achieve this goal, 
we will examine known hallmarks of DCMP in two tissue-engineered models developed 
in our lab. This will be accomplished by containing tissue-engineered myocardium made 
by combining human cardiomyocytes and decellularized porcine myocardium in (1) a 3D 
Kube minibioreactor or (2) an in-house electromechanical bioreactor cultured in a high 
glucose environment.  
Preliminary studies in our lab have shown cellular and extracellular alterations 
associated with DCMP in rat cardiomyocytes cultured in 3D Kube minibioreactors for 14 
days in high glucose. Within our lab we have also developed a physiologically relevant 
myocardial electromechanical bioreactor. With these encouraging results we chose to 
move forward and examine early human cardiomyocytes (hCM) modifications in the 3D 
Kube minibioreactor, as well as our electromechanical bioreactor in a simulated 
“diabetic” environment with additional glucose. We hypothesize that by creating and 
utilizing tissue engineering platforms for modelling DCMP we can elucidate early 
alterations in hCM and the ECM to determine points for diagnosis and treatment.   
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2.2 Specific Aims 
Aim 1: Ascertain if tools and methods we employ are suitable for analysis and 
highlight DCMP alterations (Presented in Chapter 3) 
Hypothesis: Methods utilized will detect alterations in the ECM and cells of the heart 
caused by hyperglycemia and dyslipidemia in the diabetic environment 
Approach: Hearts from normal and diabetic (streptozotocin type I induced) rats will be 
harvested and analyzed for this study 8 weeks after induction. Diabetic and DCMP 
cellular and ECM changes will be assessed via histological staining, western blotting, and 
specific assays. Alterations such as lipid accumulation, endogenous antioxidant 
mechanisms, advanced glycation endproduct (AGE) buildup, matrix metalloproteinase 
(MMP) activity, apoptosis, autophagy, endoplasmic reticulum (ER) stress, and 
perivascular and interstitial fibrosis. 
 
Aim 2: Assess suitability of human cardiomyocytes for the creation of a three-
dimensional (3D), dynamic in vitro model of DCMP (Presented in Chapter 4) 
Hypothesis: hCMs will be modified and respond in a hyperglycemic milieu  
Approach: Progenitor hCM will be cultured for two weeks in a high glucose 
environment (4.5g/L glucose) and compared to hCM cultured in normal glucose (1g/L 
glucose).  Immunofluorescence, western blotting, and specialized kits and assays will be 
used to analyze the two groups. Cells will be analyzed for alterations such as lipid 
accumulation, lipid peroxidation, reactive oxygen species (ROS) generation, endogenous 
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antioxidant mechanisms, AGE buildup, receptor for AGE (RAGE) expression, MMP 
activity, apoptosis, autophagy, and ER stress. 
 
Aim 3: Develop a myocardial-like tissue platform using proper biochemical, 
mechanical, and electrical cues (Presented in Chapter 5) 
Hypothesis: Applying specific mechanical, electrical, and biochemical stimuli, 
cardiomyocytes seeded on scaffolds will mimic the organization and function of 
myocardial tissues  
Approach: hCM from Aim 2 will be seeded into decellularized porcine myocardium and 
exposed to mechanical and electrical stimuli for 14 days via a modified Flexcell 
bioreactor to induce cell organization. Static controls will be cultured in tandem. Cell 
viability, as well as the presence of specific cardiac cell markers, such as connexin 43, 
sarcomeric α-actinin, desmin, and GATA-4 will be assessed. The extracellular matrix 
will also be analyzed for changes in collagen IV and laminin expression.    
 
Aim 4: Investigate cardiac cell and matrix modifications induced by oxidative stress 
in diabetic environment (Presented in Chapter 6) 
Hypothesis: High glucoxidative environments induce pathological modifications in cells 
and extracellular matrix 
Approach: Lipid accumulation, endogenous antioxidant mechanisms, AGE accrual, 
MMP activity, apoptosis, autophagy, and ER stress will be assessed after the myocardial-
like tissue is exposed to physiological-like conditions in vitro in either normal (1 g/L) or 
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high (4.5 g/L) glucose. Two bioreactor platforms will be tested for 14 days: (1) a 3D 
Kube perfusion minibioreactor and (2) an electromechanical bioreactor developed in our 
lab (from Aim 3).  
 
2.3 Significance of Proposed Project  
 This project is expected to have a significant impact by bridging an existing gap 
in the understanding of early alterations of human cardiac cells and the extracellular 
matrix in DCMP and the diabetic environment with tissue engineering. Development of 
an organotypic, highly reproducible, systematic model will allow for strides to be made 
not only in the clarification of DCMP, diagnosis, and patient-tailored options for 
treatment and prevention, but in validating therapies and understanding the progression of 
DCMP. 
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CHAPTER 3: CHARACTERIZATION OF AN IN VIVO DIABETIC CARDIAC 
DISEASE MODEL 
 
3.1 Introduction 
 The only cure for DCMP is a whole heart transplant.4 There is no specific marker 
for this cardiomyopathy and it is diagnosed after symptom manifestation, including but 
not limited to, shortness of breath, fatigue, chest pain, and fluid retention.5 As of now, 
treatment of DCMP is the same as other cardiomyopathies, with a focus on blood glucose 
control.2  DCMP is a complex disease and understanding its progression is the key to 
determining distinct markers for early diagnosis, as well as targeted treatments.  
Animal models have been widely utilized to understand the underlying 
mechanisms of DCMP and cardiac alterations associated with diabetes.6 One of these 
popular models is the streptozotocin (STZ) type I diabetic rat model. This type I diabetic 
rat model is produced through tail vein injection of STZ, a glucosamine-nitrosourea 
antibiotic that causes beta cell necrosis, leading to insulin deficiency.7 STZ is favorably 
up taken by beta cell GLUT2 glucose transporters in the pancreas as it has a similar 
structure to glucose.7 This diabetic rat model has been shown to exhibit decreased 
glucose utilization, increased FFA oxidation, decreased mitochondrial function, impaired 
calcium handling, and increased oxidative stress.6 
 We hypothesized that by utilizing this diabetic STZ rat model, we could detect 
alterations in the ECM and cells of the heart caused by hyperglycemia and dyslipidemia 
in the diabetic environment.  
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3.2 Materials and Methods  
3.2.1 Materials  
Streptozotocin was obtained from Sigma (S0130). Insulin used was Humulin N 
U-100 NPH from Lilly (Indianapolis, IN). AlphaTRAK® (GenII) test strip and the 
AlphaTRAK® Blood Glucose Monitoring System were from Abbot Laboratories, 
Animal Health (Abbott Park, IL). Bicinchoninic acid protein assay was from Pierce 
Biotech (Rockford, IL). Electrophoresis apparatus, gel imager and imaging software, 
chemicals, and molecular weight standards were from Bio-rad (Hercules, CA). BM 
Chemiluminescence Western Blotting kit (Mouse/ Rabbit) was obtained from Roche 
(Indianapolis, IN). The Vectastain Elite kit, ABC diaminobenzidine tetrahydrochlorine 
peroxidase substrate kit, and Vectashield mounting medium were from Vector 
Laboratories (Burlingame, CA). The following antibodies were used: rabbit anti-
superoxide dismutase-2 (Abcam, ab13534), rabbit anti-advanced glycation endproducts 
(Abcam, ab23722), rabbit anti-protein kinase RNA-like endoplasmic reticulum kinase 
(Abcam, ab192591), rabbit anti-alpha-smooth muscle actin (Abcam, ab5694), rabbit anti-
caspase-3 (Millipore, 06-735). Biotinylated anti-rabbit IgG was purchased from Vector 
Laboratories (Burlingame, CA). Movat’s Pentachrome Kit was from Poly Scientific (Bay 
Shore, NY). All other chemicals were of the highest purity and purchased from Sigma-
Aldrich Corporation (Lakewood, NJ). 
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3.2.2 Rat Streptozotocin-Induced Diabetes Model  
Diabetic rat models were produced utilizing adult male Sprague-Dawley rats 
(n=20, weight 300-350g) after tail vein injection of a single dose of sterile filtered 
55mg/kg streptozotocin (STZ) solution in 0.1M citrate buffer (pH 5). Control rats were 
given an equal volume of sterile citrate buffer (n=20). 3 days after diabetic induction, 
AlphaTRAK® (GenII) strips with the AlphaTRAK® Blood Glucose Monitoring System 
were used to measure levels of blood glucose 3-4 times a day. Diabetic rats were given 
subcutaneous injections of long-lasting insulin (2-4U Isophane) every other day after the 
establishment of diabetes (>400mg glucose/dL blood). This ensured blood glucose levels 
were maintained at reasonable ranges (400-600mg glucose/dL blood) and would prevent 
weight loss and ketonuria development. Adequate health parameters were maintained by 
closely monitoring glucose levels, individual weights, hydration status, and food and 
water consumption. Godley-Snell Research Center Animal Facility associated staff and 
attending university veterinarian provided food and water for the animals ad libitum, as 
well as animal care. 8 weeks after STZ or control injection, rats were humanely 
euthanized by carbon dioxide and hearts were harvested. Hearts for protein extraction 
were flash frozen in liquid nitrogen, transported on dry ice for storage at -20°C. For 
histological analysis, hearts were either fixed in 10% formalin before processing or 
embedded and frozen in optimal cutting temperature (OCT) compound. National Institute 
of Health (NIH) guidelines for the care and use of laboratory animals (NIH publication 
#86-23 Rev. 1996) were observed. The Animal Research Committee at Clemson 
University approved the animal protocol for this experiment. 
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3.2.3 Histological Analysis 
Rat hearts were dissected into 4 coronal sections before paraffin processing and 
embedding, for more in-depth histological analysis. Movat’s pentachrome staining was 
utilized to compare morphology between the normal and diabetic hearts (n=3 for each 
group). Rehydrated paraffin sections (5um) were stained using a Movat’s pentachrome 
kit. Manufacturer’s guidelines were followed.  
 Immunohistochemistry (IHC) was performed for detection of superoxide 
dismutase-2 (SOD-2), advanced glycation endproducts (AGE), and alpha-smooth muscle 
actin (α-SMactin) to compare diabetic and normal rat hearts (n=3 for each group). 
Briefly, antigen retrieval was performed on rehydrated paraffin sections (5um) with 
heated (90-100 degrees C, 10 min) 10mM citric acid (pH=7.4). Slides were 
permeabilized with 0.025% Triton X-100 for 5 minutes and then incubated in normal 
blocking serum for 45 minutes. Primary antibodies (rabbit anti-SOD-2 10ug/mL dilution, 
rabbit anti-AGE 4ug/mL dilution, or rabbit anti-a-SMactin 1ug/mL dilution) were 
incubated overnight at 4 degrees Celsius. Negative controls were obtained by omitting 
the primary antibody. Endogenous peroxidases were blocked with 0.3% hydrogen 
peroxide in 0.3% normal horse serum for 30 minutes. The secondary biotinylated anti-
rabbit antibody was applied for 30 minutes. Antibody staining was visualized using the 
Vector ABC peroxidase substrate kit and then lightly counterstained with diluted 
hematoxylin, before mounting. A Zeiss Axiovert 40CFL microscope with AxioVision 
Release 4.6.3 digital imaging software (Carl Zeiss MicroImaging, Inc. Thornwood, NY) 
was utilized to obtain images. 
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3.2.4 Lipid Staining  
Lipid accumulation was visualized via oil red O or sudan black staining on 
cryosectioned rat hearts (n=3 per group) and mounted with aqueous Vectashield 
mounting medium. Light images were taken on a Zeiss Axiovert 40CFL microscope, as 
described before. For oil red o, slides were fixed in 4% paraformaldehyde, rinsed in 
distilled, deionized water (ddH2O), rinsed in 60% isopropanol, and stained in 0.3% Oil 
Red O in isopropanol solution. Slides were then rinsed twice in 60% isopropanol, stained 
in a 1 to 1 hematoxylin in ddH2O solution, and rinsed in ddH2O.   
For sudan black staining, were fixed in 4% paraformaldehyde, rinsed in ddH2O, 
rinsed in 35% ethanol, followed by 70% ethanol, and stained in sudan black in 70% 
ethanol. Slides were rinsed twice in 70% ethanol, followed by a rinse in tap water, stained 
in a 1 to 1 hematoxylin in ddH2O, and rinsed in ddH2O. 
3.2.5 Detection of Caspase-3, SOD-2, AGE, and PERK 
Western blotting was employed to compare amounts of caspase-3, SOD-2, AGE, 
and protein kinase RNA-like endoplasmic reticulum kinase (PERK) between the diabetic 
(n=5) and normal (n=4) rat hearts. Proteins were extracted by pulverizing liquid nitrogen-
frozen tissue samples from the left ventricular wall and homogenizing them in 
radioimmunoprecipitation assay (RIPA) extraction buffer (50mM Tris-HCl pH 7.4, 
150mM sodium chloride (NaCl), 1mM ethylenediaminetetraacetic acid (EDTA), 1% 
Triton X-100, 1% Sodium Deoxycholate, 0.1% sodium dodecyl sulfate (SDS), with 
protease inhibitor cocktail). Protein concentrations in the samples were found using a 
bicinchoninic acid protein (BCA) assay. For each sample, 20ug of protein per lane was 
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loaded and a pre-stained molecular weight standard was loaded in one of the lanes. 
Protein from the gels were transferred to polyvinylidine fluoride membranes. Primary 
antibodies (rabbit anti-AGE 0.5ug/mL dilution, rabbit anti-SOD-2 1ug/mL dilution, 
rabbit anti-caspase-3 1ug/mL dilution, or rabbit anti-PERK 1ug/mL dilution) were 
applied overnight at 4 degrees C. The secondary antibody from the anti-mouse/rabbit kit 
was then applied for 45 minutes at room temperature. The polyvinylidine fluoride 
membranes were fluorescently tagged with detection solution from the anti-mouse/rabbit 
kit and then imaged using the Chemi-Doc™ XRS+ system from Bio-rad (Hercules, CA). 
Relative band intensities were determined using Bio-rad Image Lab Software Version 
5.1, beta build 1.  
 Relative amounts of caspase-3 within the rat hearts (n=3 per group) were 
determined with the Caspase-3 Fluorogenic Spectroscopic Assay from BD Pharmingen 
(San Jose, CA). Manufacturer’s protocol was followed. Intensities were measured using 
the Synergy H1 Hybrid Reader System from BioTek (Winooski, VT). 
3.2.6 Matrix Metalloproteinase Activity Analysis 
Protein extracts from hearts were extracted using the RIPA buffer method 
(above). Protein concentrations in the samples were found using a BCA assay. For each 
sample, 20ug of protein per lane were loaded into a gelatin zymography gel (n=2 per 
group), as was a pre-stained molecular weight standard into a separate lane. After 
electrophoresis separation, the zymography gel was washed in a triton-X solution and 
matrix metalloproteinases (MMPs) were activated with a brij-35 development buffer for 
24 hours at 37 degrees C. After staining with Coomassie, MMP clear bands were imaged 
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using the Chemi-Doc™ XRS+ system and evaluated by densitometry using the using 
Bio-rad Image Lab Software. 
3.2.7 Glutathione Detection 
Protein extracts were taken from rat hearts using the RIPA buffer extraction 
method (above). Protein concentrations in the samples were found using a BCA assay. 
Glutathione was detected in rat hearts (n=3 per group) using Cell Technology’s 
fluorescent thiol detection kit assay (Mountain View, CA). Manufacturer protocol was 
utilized. Intensities were measured the Synergy H1 Hybrid Reader System. 
3.2.8 Statistical Analysis 
 Results are expressed at mean ± standard deviation (SD). Statistical analysis was 
performed between groups utilizing Welch’s two-tailed t-test in excel. Significance was 
determined with an alpha (α) value of 0.05. 
3.3 Results 
3.3.1 Extracellular Matrix Analysis 
 Analysis of normal and diabetic rat hearts was performed to determine if ECM 
changes associated with DCMP were noticeable. On the macro scale, diabetic hearts 
markedly enlarged and dilated when compared to normal rat hearts (Figure 3.1). As seen 
in Figure 3.2, diabetic rat hearts had higher instances of fibrosis within the myocardium 
of the left ventricle and blood vessels, as revealed by Movat’s pentachrome staining and 
IHC staining of α-SMactin. Analysis of MMPs revealed reduced activity in diabetic rat 
hearts (Figure 3.3).  
 71 
 
Figure 3.1: Harvested diabetic (bottom) and normal (top) rat hearts. 
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Figure 3.2: Extracellular matrix (ECM) analysis of normal and diabetic rat hearts. 
Movat’s pentachrome staining (top and middle) of the left ventricle and blood vessels 
(black=nuclei or elastic fibers, yellow=collagen or reticular fibers, blue=ground 
substance or mucin, bright red=fibrin, red=muscle) in hearts. Immunohistochemistry 
(IHC) staining (bottom) was used for α-smooth muscle actin (α-SMactin, 
brown=positive, dark purple=nuclei) visualization. Negative controls not shown for IHC. 
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Figure 3.3: Matrix metalloproteinase (MMP) activity assessment in rat hearts. Gelatin 
zymography was used to determine MMP activity in diabetic and normal rat hearts. 
RDU= relative densitometry units. 
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Figure 3.4: Advanced glycation endproducts (AGE) formation within normal and 
diabetic rat hearts. (A) Hearts were stained for AGEs via immunohistochemistry (IHC) 
(brown=positive, dark purple=nuclei). (B) AGEs in hearts were analyzed with western 
blotting. RDU= relative densitometry units. 
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Figure 3.5: Lipid accumulation staining in diabetic and normal rat hearts. Lipids in 
hearts were visualized with oil red O (red=lipids) and sudan black (black=lipids) staining.  
 
Figure 3.6: Investigation of apoptosis in rat hearts. Relative expression of caspase-3, an 
apoptosis marker, was measured with (A) a caspase-3 assay and (B) western blotting. * 
indicates statistical significance. RDU=relative densitometry units.  
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3.3.2 AGE Formation, Lipid Accumulation, and Apoptosis 
 As hyperglycemia and hyperlipidemia are hallmarks of DM and DCMP, we 
sought to compare diabetic rat hearts to normal rat hearts for glycoxidation and lipid 
accumulation. As shown in Figure 3.4, AGEs were present in both normal and diabetic 
rat heart tissue, as seen in IHC AGE staining. Western blot protein analysis of AGEs 
showed no significant difference between normal and diabetic rat hearts. AGE staining of 
blood vessels of the hearts demonstrated increased circulating AGEs in diabetic rat 
hearts. Staining of lipids via oil red O and sudan black, displayed higher lipid 
accumulation within the diabetic rat heart tissue (Figure 3.5). Hyperglycemia and 
hyperlipidemia can both lead to programmed cell death, known as apoptosis. Caspase-3, 
a marker of apoptosis, was used to investigate this. It was found via western blotting and 
a specific caspase-3 assay that caspase-3 expression was significantly increased, and 
therefore apoptosis, in diabetic rat hearts compared to normal rat hearts (Figure 3.6). 
3.3.3 Antioxidant Defense Mechanisms and Endoplasmic Reticulum Stress  
 One element of DCMP is oxidative stress caused by an imbalance between 
reactive oxygen species (ROS) and antioxidant defense mechanisms, such as SOD-2 and 
glutathione. As observed in Figure 3.7, there was a significant reduction in SOD-2 and 
glutathione expression in diabetic rat hearts. IHC revealed normal rat hearts to have 
SOD-2 expressed throughout the tissue, while SOD-2 expression in diabetic rat hearts 
were concentrated in the myocardium. Western blot protein detection showed SOD-2 was 
significantly decreased in diabetic rat hearts. Glutathione content in diabetic rat hearts 
was also significantly decreased as measured by a glutathione assay. 
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Figure 3.7: Antioxidant defense mechanisms utilized by normal and diabetic rat hearts. 
Superoxide dismutase-2 (SOD-2) was visualized with immunohistochemistry (IHC) (top) 
(brown=positive, dark purple=nuclei) and detected with western blotting (bottom left); 
results are in relative densitometry units (RDU). Glutathione was measured via an assay 
(bottom right). 
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Another trait of diabetes and DCMP is ER stress within cells due to buildup of 
misfolded proteins. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) is 
upregulated in ER stress and its pathway triggers the unfolded protein response. Western 
blotting of this protein showed an upward trend in diabetic rat hearts.  
 
Figure 3.8: Endoplasmic reticulum (ER) stress in normal and diabetic rat hearts. Protein 
kinase RNA-like endoplasmic reticulum kinase (PERK), a marker for ER stress, was 
detected by western blotting. RDU= relative densitometry units. 
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3.4 Discussion 
 Experimental animal models have been employed for understanding 
cardiovascular alterations associated with diabetes, specifically DCMP. Known hallmarks 
of this disease at the cellular and extracellular levels, include fibrosis, buildup of AGEs, 
lipid accumulation, oxidative stress, ER stress, apoptosis, and autophagy.8 In this study 
we sought to use a diabetic rat model to see if there were noticeable ECM and cellular 
alterations in the hearts associated with DCMP. We also wanted to optimize the tools and 
methods we were using in investigating and perceiving these changes.  
The STZ diabetic type 1 model used for this study provided a baseline, as it has 
been thoroughly studied in literature and diabetic rat hearts from this experimental model 
have been shown to display alterations and characteristics of DCMP.6 STZ is a popular 
diabetic rodent model as it is easily administered to the animal and takes less time to 
produce than genetic diabetic rodent models.7 This model can also be combined with 
genetically altered rodents, making it favorable for specific research into genetic 
disorders combined with diabetes, exacerbated diabetic models, and knock out models.9,10 
While this is a popular experimental model, there are disadvantages that have been noted 
with intravenous STZ administration to create this diabetic state. One of the most 
significant is systemic genotoxic effects from the injected STZ.11 Kume et. al. reported 
that there are changes in hepatic gene expression, such as downregulation of genes 
associated with lipid metabolism and glucose as soon as 48 hours after STZ 
administration. These modifications occurred before a rise in blood glucose levels, 
implying that genes unrelated to hyperglycemia might be altered.12 It has also been 
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suggested that through a p38 mitogen-activated protein kinase-dependent oxidative stress 
mechanism STZ reduces cardiac function.13 Problems can also arise within this model, as 
the intensity of diabetes developed within STZ treated rats can differ, explicitly seen in 
lack of mitochondrial dysfunction in STZ diabetic rats without ketosis.14 
Within rat hearts that were treated with STZ and diabetic for 8 weeks, there were 
noticeable changes to the ECM as reported before, such as fibrosis.15,16 Upon 
observation, diabetic rat hearts were increased in size and dilated when compared to 
normal hearts. Interstitial fibrosis was noticeably spread through the endocardium and 
myocardium of left ventricle of diabetic rat hearts, whereas it was not in normal rat 
hearts. Perivascular fibrosis within the diabetic myocardium was also noticed with an 
increased amount of collagen and thickened walls. This could be due to an imbalance 
between collagen production and degradation, as MMP activity was also lowered in 
diabetic hearts. The diabetic condition is a prolonged, highly inflammatory state and 
inflammation activates increased collagen production through myofibroblast 
activation.17,18 
As the hyperglycemia and dyslipidemia are traits of a diabetic environment, we 
investigated glycoxidation, specifically the presence of AGEs, and lipid accumulation 
within the rat heart tissue.19,20 We found there was no significant difference in AGE 
expression within the tissue of normal and diabetic hearts, however AGEs circulating 
within diabetic blood vessels was visibly higher as seen in staining. AGEs are naturally 
occurring within tissue.19 8 weeks may have been too short of a time for AGEs to become 
overexpressed in the diabetic heart tissue and longer timepoints may be needed to see 
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over accumulation of AGEs in the tissue. Also, the AGE marker utilized for this study is 
a pan AGE marker. Other specific AGE markers, such as carboxymethyl lysine, could 
show significant differences between the hearts.21 Diabetic hearts had noticeably 
increased lipid accumulation when compared to normal hearts. This has also been noted 
in literature.22,23  
Programmed cellular death or apoptosis is another hallmark of DCMP. Metabolic 
changes, such as FFA usage and oxidative stress, lead to apoptosis. Caspase-3, an 
apoptosis marker, was significantly increased in diabetic rat hearts. Apoptosis has been 
shown to be increased in the STZ diabetic rat hearts.24,25  
As oxidative stress is increased in the diabetic environment, we examined 
antioxidant defense mechanisms to determine if there were differences between the 
hearts.26 SOD-2 and glutathione, endogenous cellular antioxidants, were investigated.27 
SOD-2 expression was sequestered in the myocardium of diabetic rat hearts, while SOD-
2 was homogenously throughout normal hearts. SOD-2 and glutathione were both 
significantly reduced in diabetic rat hearts, illustrating that antioxidant defense 
mechanisms within these hearts are either hindered within the diabetic environment or 
have been depleted through excessive utilization. 
ER stress has also been shown to be increased in the diabetic environment due to 
misfolded or unfolded proteins within the ER.28 In this state, PERK is activated and 
triggers the unfolded protein response (UPR) pathway to control protein quality.29 In 
diabetic rat hearts it was found that there was an upward trend of PERK, showing that ER 
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stress was slightly higher in diabetic rat hearts. This is however, one of three major 
pathways that can be activated and one facet of the story.  
3.5 Conclusions 
 STZ type 1 diabetic rat models are useful for investigating ECM and cellular 
changes associated with DCMP in vivo, however there are discrepancies within the 
severity of diabetes in this model and systemic STZ administration does not allow for a 
full recapitulation diabetes seen in human patients. The tools and methods we employed 
in this diabetic rat heart study are suitable for analysis and highlighted DCMP alterations. 
These techniques will be useful for future studies into this disease.  
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CHAPTER 4: ASSESMENT OF A 2D IN VITRO HUMAN CARDIOMYOCYTE 
DIABETIC CARDIAC MODEL  
 
4.1 Introduction  
Cardiomyocyte (CM) adaptations in response to the diabetic environment are of 
interest in the beginning stages of diabetic cardiomyopathy (DCMP). CMs are 
responsible for contraction of the myocardium and when they are compromised, so is 
overall functionality of the heart.1 Hyperglycemia and dyslipidemia in the diabetic 
milieu, lead to a loss of metabolic flexibility within the cell.2 Free fatty acids are 
preferentially used as an energy source, followed by lipid accumulation and peroxidation, 
with the over formation of reactive oxygen species (ROS).3 ROS is produced faster than 
the cell can eliminate it through endogenous antioxidant defenses, causing oxidative 
stress.4,5 Cellular autophagy and apoptosis follow prolonged oxidative stress.6,7 Within 
this diabetic climate, advanced glycation endproducts (AGEs) aggregate, forming 
irreversibe crosslinks, with a decrease in matrix metalloproteinase (MMP) activity.8 This 
imbalance gives rise to tissue fibrosis. CMs become hypertrophic as they must work that 
much harder to maintain efficiency to compensate for CM loss and tissue stiffening.9 
Overtime, this can lead to heart failure.  
 To understand CM modifications in the diabetic environment, two-dimensional 
(2D) cell culture of this cell type has been employed with the addition of glucose to the 
cell culture media. Cells such as neonatal rat CMs, induced pluripotent stem cells 
(iPSCs), progenitor CMs, immortalized CMs, and embryonic stem cells (ESCs) have 
been utilized for these studies and have shown to be altered under these conditions.10–15 
We chose to investigate human progenitor CMs (hCMs) as they are commercially 
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available, able to expand in culture, adult human cells, and there were no ethical concerns 
attached, as there are with ESCs.16 We hypothesized that we would see alterations and 
responses in these hCMs known in the diabetic state by culturing them with additional 
glucose. The goal of this initial study was to determine if these cells would be suitable for 
the creation of a three-dimensional (3D), dynamic in vitro model of DCMP. 
4.2 Materials and Methods  
4.2.1 Materials 
Progenitor human cardiac myocytes (hCM) were from Promocell GmbH 
(Heidelberg, Germany). Dulbecco’s Modified Eagle Medium (DMEM) and antibiotic / 
antimycotic were from Corning Incorporated (Oneonta, NY). Fetal Bovine Serum (FBS) 
was from Atlanta Biologicals (Atlanta, GA). Bicinchoninic acid protein assay was from 
Pierce Biotech (Rockford, IL). Electrophoresis apparatus, gel imager and imaging 
software, chemicals, and molecular weight standards were from Bio-rad (Hercules, CA). 
BM Chemiluminescence Western Blotting kit (Mouse/ Rabbit) was obtained from Roche 
(Indianapolis, IN). Paraformaldehyde was from Electron Microscopy Sciences (Hartfield, 
PA). Triton X-100 was from Alfa Aesar (Ward Hill, MA). Bovine Serum Albumin was 
from Rockland Immunochemicals Inc. (Limerick, PA). The following antibodies were 
used: rabbit anti-superoxide dismutase-2 (Abcam, ab13534), rabbit anti-caspase-3 
(Millipore, 06-735 or Abcam, ab32042), rabbit anti-receptor for advanced glycation 
endproducts (Abcam, ab37647), mouse anti-N-epsilon-(carboxylmethyl)lysine (R&D 
Systems, MAB3247), rabbit anti-light chain 3B (Abcam, ab48394), and rabbit anti-
protein kinase RNA-like endoplasmic reticulum kinase (Abcam, ab192591). Alexa 
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Fluor® fluorescent secondary antibodies (mouse and rabbit) were purchased from 
Molecular Probes (Eugene, OR). All other chemicals were of the highest purity and 
purchased from Sigma-Aldrich Corporation (Lakewood, NJ). 
4.2.2 Culture of Human Cardiomyocytes 
 Progenitor human cardiac myocytes (hCMs) were cultured for 14 days in normal 
glucose and high glucose media. Normal and diabetic media constituted of Dulbecco’s 
Modified Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS), and 1% 
antibiotic/antimycotic (penicillin-streptomycin), with 5mM (1g/L) and 25mM (4.5g/L) 
glucose, respectively.    
4.2.3 Immunofluorescence for Caspase-3, SOD-2 and CML/RAGE  
 Immunofluorescence was used for the visualization of caspase-3, superoxide 
dismutase 2 (SOD-2,) and carboxymethyl lysine/receptor for advanced glycation 
endproduct (CML/RAGE) in normal and high glucose conditioned hCMs. Cells were 
fixed with 4% warm paraformaldehyde for 20 minutes and then permeabilized with 0.2% 
Triton X-100 (10 minutes) at room temperature. A blocking solution of 5% bovine serum 
albumin and 0.05% Triton X-100 was then applied for 45 minutes. Cells were incubated 
in primary antibodies (rabbit anti-caspase-3 Abcam 1ug/mL, rabbit anti-SOD-2 at 
4ug/mL, or mouse anti-CML at 1ug/mL and rabbit anti-RAGE at 1ug/mL) in a 1 to 1 
mixture of blocking solution to phosphate buffered saline for 2 hours.  For negative 
controls, a 1 to 1 solution of blocking solution to phosphate buffered saline was used, 
without primary antibodies. Alexa Fluor® fluorescent secondary antibodies (anti-rabbit 
or anti-mouse) were applied for 1 hour at room temperature. Cell nuclei were stained 
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with 4’,6-diamidino-2-phenylindole (DAPI) and a Zeiss Axiovert 40CFL microscope 
with AxioVision Release 4.6.3 digital imaging software, UV light box, and filter from 
Carl Zeiss MicroImaging, Inc. (Thornwood, NY), was utilized to obtain 
immunofluorescence images. 
4.2.4 Detection of Caspase-3, SOD-2, CML, and LC3B 
  Western blotting was employed to compare amounts of caspase-3, SOD-2, CML, 
light chain 3B (LC3B), and protein kinase RNA-like endoplasmic reticulum kinase 
(PERK) between normal glucose (n=3,4,4,4,4 respectively) and high glucose (n=3,4,4,5,3 
respectively) conditions. Proteins were extracted by radioimmunoprecipitation assay 
(RIPA) extraction buffer (50mM Tris-HCl pH 7.4, 150mM sodium chloride (NaCl), 
1mM ethylenediaminetetraacetic acid (EDTA), 1% Triton X-100, 1% Sodium 
Deoxycholate, 0.1% sodium dodecyl sulfate (SDS), with protease inhibitor cocktail). 
Protein concentrations in the samples were found using a bicinchoninic acid protein 
(BCA) assay. For each sample, 20ug of protein per lane was loaded and a pre-stained 
molecular weight standard was loaded in one of the lanes. Protein from the gels were 
transferred to polyvinylidine fluoride membranes. Primary antibodies (rabbit anti-
caspase-3 Millipore 1ug/mL, rabbit anti-SOD-2 1ug/mL, mouse anti-CML 1ug/mL, 
rabbit anti-LC3B 1ug/mL, or rabbit anti-PERK 1ug/mL) were applied overnight at 4°C. 
The secondary antibody from the anti-mouse/rabbit kit was then applied for 45 minutes at 
room temperature. The polyvinylidine fluoride membranes were fluorescently tagged 
with detection solution from the anti-mouse/rabbit kit (1 minute) and then imaged using 
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the Chemi-Doc™ XRS+ system from Bio-rad (Hercules, CA). Relative band intensities 
were determined using Bio-rad Image Lab Software Version 5.1, beta build 1.  
Relative amounts of caspase-3 within cell cultures were examined with the 
ApoTarget Caspase-3 / CPP32 Colorimetric Protease Assay from Invitrogen (Carlsbad, 
CA). Manufacturer’s protocol was followed. Total protein was measured via a BCA 
assay and 100ug was used per sample (n=2 per group). Intensities were measured using 
the Synergy H1 Hybrid Reader System from BioTek (Winooski, VT). 
4.2.5 Matrix Metalloproteinase Activity Analysis 
 Protein extracts from hCMs were taken from normal (n=4) and high (n=4) 
glucose groups using the RIPA buffer extraction method (above). Protein concentrations 
in the samples were found using a BCA assay. For each sample, 20ug of protein per lane 
were loaded into a gelatin zymography gel, as was a pre-stained molecular weight 
standard into a separate lane. After electrophoresis separation, the zymography gel was 
washed in a triton-X solution and matrix metalloproteinases (MMPs) were activated with 
a brij-35 development buffer for 24 hours at 37 degrees C. After staining with 
Coomassie, MMP clear bands were imaged using the Chemi-Doc™ XRS+ system and 
evaluated by densitometry using the using Bio-rad Image Lab Software. 
4.2.6 Lipid Accumulation and Peroxidation Staining 
 Intracellular lipid accumulation was visualized via Oil Red O staining. Briefly, 
cells were fixed in 4% paraformaldehyde, rinsed in distilled deionized water (ddH2O), 
rinsed in 60% isopropanol, and stained in 0.3% Oil Red O in isopropanol solution. Cells 
were then rinsed twice in 60% isopropanol, stained in a 1 to 1 hematoxylin to ddH2O 
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solution, and rinsed in ddH2O.  Light images were taken on a Zeiss Axiovert 40CFL 
microscope with AxioVision Release 4.6.3 digital imaging software from Carl Zeiss 
MicroImaging, Inc. (Thornwood, NY). 
 Lipid peroxidation was investigated in normal and high glucose hCM cultures by 
employing the Click-iT® Lipid Peroxidation Detection with Linoleamide Alkyne Kit 
from Molecular Probes (Eugene, OR). Manufacturer protocol was utilized. Cells nuclei 
were stained with DAPI and imaged via the immunofluorescence protocol previously 
discussed (above). 
4.2.7 Reactive Oxygen Species Generation Analysis 
Reactive oxygen species (ROS) generation in normal and high glucose hCM 
cultures were determined by utilizing the CellROX® Oxidative Stress Reagents Kit from 
Molecular Probes (Eugene, OR). Manufacturer protocol was utilized. Cell nuclei were 
stained with DAPI and imaged using immunofluorescence protocol mentioned previously 
(above).  
4.2.8 Autophagy Inspection 
 Autophagy in normal and high glucose conditioned hCMs was studied by 
utilizing the LC3B Antibody Kit for Autophagy from Invitrogen (Carlsbad, CA). 
Manufacturer protocol was utilized. Cell nuclei were stained with DAPI and 
immunofluorescence images were captured as discussed before (above). 
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4.2.9 Statistical Inquiry 
Results are expressed at mean ± standard deviation (SD). Statistical analysis was 
performed between groups utilizing Welch’s two-tailed t-test in excel. Significance was 
determined with an alpha (α) value of 0.05. 
4.3 Results 
4.3.1 Advanced Glycation Endproducts and Matrix Metalloproteinase Activity 
 Analysis of in vitro 2D hCM cultures after two weeks in normal or high glucose 
was performed to determine if there were noticeable changes in expression of advanced 
glycation endproducts (AGEs) with their receptor (RAGE) and matrix metalloproteinase 
(MMP) activity. Immunofluorescence images of carboxymethyl lysine (CML), an AGE, 
and RAGE, showed greater expression of both in high glucose hCM cultures when 
compared to hCM cultured in normal glucose (Figure 4.2). Based on western blotting, 
CML illustrated an upward trend in high glucose hCM treated cells. There was a 
downward trend in MMP activity in high glucose cultured hCM as revealed by gelatin 
zymography of protein lysates (Figure 4.1).  
4.3.2 Lipotoxicity and Reactive Oxygen Species Formation 
 Determination of lipotoxicity and reactive oxygen species (ROS) in normal and 
high glucose hCM cultures was executed with oil red O lipid staining and specialized kits 
for lipid peroxidation and ROS detection. By using the Click-iT® Lipid Peroxidation 
Detection with Linoleamide Alkyne Kit, we were able to observe increased lipid 
peroxidation within hCM cultured in high glucose (Figure 4.3). hCM cultured in high 
glucose also showed higher lipid accumulation as visualized by oil red O lipid staining. 
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ROS aggregation was examined with the CellROX® Oxidative Stress Reagents Kit. It 
was noticed that high glucose hCM had more formation of ROS, than normal glucose 
hCM.  
 
Figure 4.1: Matrix metalloproteinase (MMP) activity analysis. Gelatin zymography was 
used to compare MMP activity in high and normal glucose hCM conditions. 
RDU=relative densitometry units. 
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Figure 4.2: Advanced glycation endproducts and their receptor in hCM high and normal 
glucose cell culture. (A) Immunofluorescence staining for an advanced glycation 
endproduct, carboxymethyl lysine (CML, green), receptor for advanced glycation 
endproducts (RAGE, red), and staining with 4’,6-diamidino-2-phenylindole (DAPI) for 
nuclei (blue) in hCM cell cultures. Negative controls not shown. (B) Western blotting for 
CML in hCM cultures. RDU=relative densitometry units.  
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Figure 4.3: Lipotoxicity and reactive oxygen species formation in hCM culture. Lipid 
peroxidation staining (green) of hCM in normal and high glucose conditions with Click-
iT® Lipid Peroxidation Detection with Linoleamide Alkyne Kit and nuclei staining 
(blue) with DAPI (top). Oil red O lipid staining (red) in hCM culture (middle) with cell 
hematoxylin staining (purple). Reactive oxygen species (ROS) visualization (green) in 
hCM culture with CellROX® Oxidative Stress Reagents Kit and DAPI nuclei staining 
(blue).  
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4.3.3 Endoplasmic Reticulum Stress and Superoxide Dismutase-2 Antioxidant Defense   
 Endoplasmic reticulum stress was analyzed with a marker, protein kinase RNA-
like endoplasmic reticulum kinase (PERK). Western blotting detection showed no 
statistical difference between groups (Figure 4.4). Endogenous antioxidant defenses 
against ROS were assessed in normal and high glucose conditioned hCM by investigating 
expression of superoxide dismutase-2 (SOD-2), a cellular mitochondrial scavenger. 
Immunofluorescence staining of SOD-2 in hCM showed that this protein was expressed 
in both normal and high glucose cultures (Figure 4.5). Western blotting protein analysis 
of SOD-2, also confirmed this, as there was no difference in expression between groups.  
4.3.4 Apoptosis and Autophagy 
 Programmed cellular apoptotic death and autophagic organelle recycling were 
assessed in hCM normal and high glucose cultures to see if high glucose conditions 
induced these outcomes, as seen in diabetic conditions. Immunofluorescence staining for 
caspase-3, an apoptosis marker, illustrated higher caspase-3 expression in high glucose 
hCM when compared to normal glucose hCM (Figure 4.6). Examination of caspase-3 in 
protein lysates by an assay revealed an upward trend of apoptosis in hCM in high 
glucose, however western blotting of caspase-3 western blotting showed no difference 
between the two groups. Visualization of light chain 3B (LC3B), an autophagy marker, 
was performed with the LC3B Antibody Kit for Autophagy and showed increased 
expression in high glucose hCM (Figure 4.7). Western blotting investigation of LC3B 
demonstrated an upward trend with high glucose conditioning of hCM compared to 
normal hCM.  
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Figure 4.4: Endoplasmic reticulum stress examination in normal and high glucose hCM 
culture. Western blotting of protein kinase RNA-like endoplasmic reticulum kinase 
(PERK), an ER stress marker. RDU= relative densitometry units. 
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Figure 4.5: Analysis of superoxide dismutase-2 (SOD-2) antioxidant defense in high and 
normal glucose hCM cultures. (A) Immunofluorescence staining of SOD-2 (green) with 
DAPI (blue) nuclei staining of hCM. Negative controls not shown. (B) Western blotting 
for SOD-2 expression in hCM culture. RDU=relative densitometry units. 
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Figure 4.6: Apoptosis in hCM normal and high glucose culture. (A) 
Immunofluorescence for caspase-3 (green), an apoptosis marker, with DAPI (blue) nuclei 
staining in hCM culture. Negative controls not shown. (B) Caspase-3 assay and (C) 
western blotting was used for caspase-3 for apoptosis detection in normal and high 
glucose conditioning of hCM. RDU=relative densitometry units.  
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Figure 4.7: Autophagy investigation in high and normal glucose environments for hCM. 
(A) Autophagy visualization in hCM employing light chain 3B (LC3B, green) Antibody 
Kit for Autophagy staining with nuclei staining via DAPI (blue). Negative controls not 
shown. (B) Western blotting of hCM protein lysates for LC3B, an autophagy marker. 
RDU=relative densitometry units. 
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4.4 Discussion 
 Cell culture has provided a simple and controllable in vitro model over the years 
to study normal cellular function and disease related alterations that occur within specific 
cardiac cell types, such as CMs, fibroblasts, endothelial, and smooth muscle cells.17–19 
These studies have provided starting points for research into regulatory pathways 
important for healthy cell function, as well as underlying mechanisms of pathological 
disease progression. Modifications at the micro cellular level ultimately lead to macro 
functional problems at the tissue, organ, and system levels. Understanding how 
specialized cells within a tissue operate and adapt within a disease are the keys to 
diagnosis of the patient and provide targets for treatment.  
 While cell culture is great for initial studies, its simplistic and static nature does 
have some pitfalls. The human body is a highly complicated and dynamic machine with 
many mechanisms still to be understood. Cell culture models are reproducible and cell 
media is easily tailored with the addition of chemicals, however diseases exist on a 
spectrum and across multiple systems in the body.20 Media does not include important 
aspects, such as paracrine factors from other cells. Crosstalk via paracrine factors 
between cells and cell types within an altered state can influence how they themselves 
change in response, such as CM hypertrophy and fibroblast proliferation in cardiac 
disease.21 In standard culture, cells are grown on a 2D negatively charged polystyrene 
surface. Extracellular matrix components, such as collagen and fibronectin, can be used 
as surface coatings to better mimic the physiologic environment, however, this still does 
not capture the sophistication of the human body.22 
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 We sought to investigate and characterize cells in an in vitro 2D DCMP model 
before pursuing usage within a more complicated 3D in vitro disease model. Early 
alterations of CMs are still not understood within this disease, making it difficult to 
determine targeted therapies and diagnostic markers for DCMP.23 Throughout the years, 
CMs, such as neonatal rat CMs, iPSCs differentiated into CMs, progenitor CMs, 
immortalized CMs, and ESCs, have been utilized by many research groups for 
understanding cellular adaptations in myocardial diseases as well as diabetic studies.10,13–
15,24,25 For our study we decided to use human progenitor CMs (hCMs), as they were 
commercially available, able to expand in culture, adult human cells, and there were no 
ethical concerns attached, like ESCs.16 It is important to note that while these cells are 
isolated from adult hearts, they have characteristics unlike adult CMs, such as the ability 
to proliferate and potential to differentiate. These specific cells from the manufacturer 
have been used for many applications such as inflammatory, hypoxic, metabolic, toxicity, 
and pharmacological studies.13,26–31  
 For this preliminary study of a simple 2D DCMP model, the “diabetic” 
environment was produced by the addition of glucose to culture media. After two weeks, 
cells were analyzed for alterations known to exist within DCMP, such as lipid 
accumulation and peroxidation, ROS formation, increased cell death and autophagy, 
accumulation of AGEs with increased expression of their receptor, RAGE, endoplasmic 
reticulum (ER) stress, changes in endogenous antioxidant defense mechanisms, and 
lessened MMP activity.32,33 This was performed to determine if these cells would be 
suitable for future studies.  
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 Hallmarks of diabetes and DCMP include the accumulation of AGEs and 
increased expression of its receptor, RAGE.34,35 The hyperglycemic environment leads to 
the buildup of these irreversible crosslinks, which can detrimentally alter the extracellular 
matrix.36 As the diabetic state is highly inflammatory, RAGE becomes overexpressed via 
a positive feedback cycle.37 This was also shown to be the case within our in vitro model 
as CML, an AGE, and RAGE expression were increased when cultured in high glucose. 
We also investigated MMP activity, as in DCMP it is inhibited.38 Within our model, there 
was a downward trend in the high glucose groups.  
 Hyperglycemia and dyslipidemia in diabetes cause loss of metabolic plasticity, 
leading to a surge in usage of free fatty acids.32 From this imbalance oxidative stress, ER 
stress, lipid peroxidation, and lipid aggregation originate.5 There were noted increases of 
all these features, except for ER stress, in the high glucose cultures of hCM. Increases in 
all of these traits have been previously reported in high glucose studies involving 
neonatal and adult rat CMs, hiPSCs, and progenitor hCM sourced from the same 
company.10,12,13,39,40 ER stress was not shown to be increased in high glucose cell culture 
conditions, however this study was only for two weeks and only a marker for one of three 
pathways activated by ER stress was investigated. It may be worthwhile to look at other 
pathway markers, as they may activated at earlier timepoints.  
These metabolic disturbances and unbalanced state can lead to overwhelmed 
antioxidant defense mechanisms followed by enhanced cellular organelle recycling via 
autophagy and increased programmed cell death through apoptosis.6,41 There were no 
differences seen in the expression of SOD-2, an endogenous mitochondrial defense 
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mechanism, between the two groups within two weeks. Autophagy and apoptosis were 
increased in high glucose hCM. Escalation of apoptosis in inflated glucose conditions has 
been seen in hiPSCs differentiated into CMs and neonatal rat CMs.10,11 
4.5 Conclusions 
 Cell culture is a good stepping stone for initial investigations of homeostatic 
cellular functions and pathological alterations of specific cell types, however it is unable 
to recapitulate the complexity or diversity of the human body. Progenitor hCM utilized 
for this preliminary study responded to the “diabetic” environment induced with the 
addition of glucose for two weeks. They will be useful in building a tissue engineered 
DCMP model to study early cellular changes in a 3D and dynamic in vitro model. 
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CHAPTER 5: ELECTROMECHANICAL BIOREACTOR FOR CARDIAC 
TISSUE ENGINEERING  
 
5.1 Introduction 
 Tissue engineering holds a great promise to regenerate myocardial tissue in order 
to replace and restore function to the diseased tissue. To do this a robust system is needed 
to condition the construct (i.e. the scaffold and cells) prior to implantation for tissue 
maturation. Physiological electromechanical stimuli are crucial in this process as they 
improve maturation, structure, and function of cardiomyocytes (CMs) in vitro.1 Electrical 
stimulation of CMs has been shown to affect cell alignment, differentiation, metabolic 
activity, protein synthesis, connexin 43 expression, conduction velocity, calcium 
handling, and force generation.2 These changes have been induced with physiological 
electrical properties such as rectangular shape and 2ms duration at 5V/cm and 1Hz.3 
Mechanical strain is important for CM alignment and development and expression of t-
tubules, myofilaments, sarcomeric organization, gap junctions, desmosomes, adherens 
junctions.4 
As of now, combinational electromechanical bioreactors have only tested animal 
cells in gels at low cyclic stretch or decellularized myocardium for a short duration.5,6 
However, many discrepancies exist between animal and human CMs, gels may not 
withstand the highly dynamic environment seen in vivo, and scaffolds tested would be 
too small to be translatable for use in a human patient.7,8 To meet this need, we developed 
a physiologically relevant electromechanical bioreactor system. We hypothesized that by 
combining this with a methodology for reproducible myocardial-like tissues utilizing 
decellularized porcine myocardium, previously developed in our lab, seeded with human 
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CMs we would be able to create a robust platform for tissue engineered myocardium 
preconditioning. 
5.2 Materials and Methods 
5.2.1 Materials 
Primary human cardiac myocytes (hCM) were from Promocell GmbH 
(Heidelberg, Germany). Dulbecco’s Modified Eagle Medium (DMEM) and 
antibiotic/antimycotic were from Corning Incorporated (Oneonta, NY). Fetal Bovine 
Serum (FBS) was from Atlanta Biologicals (Atlanta, GA). A FX-5000™ Compression 
System and Bioflex® 6-well plates were from Flexcell International Corp. (Burlington, 
NC, USA). Bicinchoninic acid protein assay was from Pierce Biotech (Rockford, IL). 
Carbon electrodes were from Alfa Aesar (Haverhill, MA). Platinum wire was purchased 
from Ladd Research Industries (Williston, VT). The Vectastain Elite kit, ABC 
diaminobenzidine tetrahydrochlorine peroxidase substrate kit, and Vectashield mounting 
medium were from Vector Laboratories (Burlingame, CA). The following antibodies 
were used: rabbit anti-sarcomeric α-actinin (Abcam, ab90776), rabbit anti-connexin-43 
(Abcam, ab11370), rabbit anti-GATA-4 (Abcam, ab84593), rabbit anti-desmin (Abcam, 
ab15200), rabbit anti-laminin (Abcam, ab11575), and rabbit anti-collagen IV (Abcam, 
ab6586). Biotinylated anti-rabbit IgG was purchased from Vector Laboratories 
(Burlingame, CA). Movat’s Pentachrome Kit and Masson’s Trichrome Kit were from 
Poly Scientific (Bay Shore, NY). All other chemicals were of the highest purity and 
purchased from Sigma-Aldrich Corporation (Lakewood, NJ). 
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5.2.2 Decellularization of Porcine Myocardium Scaffold 
Whole, healthy, porcine hearts were obtained from a local abattoir and 
decellularized utilizing a previously published method.9 Briefly, after harvesting whole 
hearts were immediately injected with warm 50mM ethylenediamenetetraacetic acid 
(EDTA) in phosphate buffered saline (PBS) into the coronary arteries to prevent clotting. 
Hearts were transported on ice for processing. Pulmonary veins were cannulated with a 
threaded plug and zip-ties, to ensure proper circulation of solution and decellularization 
through the left side of the heart. Excess adipose and connective tissue were cleaned from 
the aorta, aortic leaflets were removed, and aorta was connected to a perfusion 
decellularization system. The hydrostatic driven perfusion decellularization system 
contained a multichannel peristaltic pump (Masterflex; Cole-Parmer) and a series of 
reservoirs that circulated 3.5L of solution through and around each heart (Figure 5.1). 
Decellularization was performed utilizing 1% sodium dodecyl sulfate (SDS) solution 
changes and a DNAse/RNase treatment. Distilled deionized water (ddH2O) and PBS were 
employed for washes. Scaffolds were stored in PBS with 0.02% sodium azide and 
0.001% protease inhibitor cocktail (Sigma) at 4 degrees C until tissue preparation. 
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Figure 5.1: Decellularized porcine myocardium scaffold preparation. (A) Whole heart 
perfusion decellularization setup utilizing hydrostatic pressure and peristaltic pump. (B) 
Container housing one heart. (C) System can decellularize three hearts simultaneously. 
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5.2.3 Tissue Preparation and Sterilization  
Decellularized porcine myocardium from the left ventricle was sliced to 2mm by 
4cm by 2 cm via a specialized tissue slicer. Briefly, the scaffold was cut into 4 cm by 2 
cm pieces using a 3D printed template. These constructs were placed flat on aluminum 
foil at -20 degrees Celsius until frozen, then cut into 2 mm slices utilizing microtome 
blades integrated into a custom tissue slicer designed in SolidWorks and 3D printed in 
digital acrylonitrile butadiene styrene (ABS). After sizing, the tissue was washed in three 
rinses of PBS (30 min, 2 hr, 30 min) and then sterilized in sterile 0.01% peracetic acid in 
PBS for 2 hours. Excess peracetic acid was removed through three washes of sterile PBS 
(30 min, 2hr, 30 min). Scaffolds were stored in sterile PBS at 4 degrees Celsius until cell 
seeding preparation. 
5.2.4 Adaptation of Flexcell Bioflex® 6-Well Plates for Tissue and Electrode Integration 
To accommodate cell-seeded scaffolds and an electrical stimulus similar to 
physiological conditions, Flexcell Bioflex® 6-well plates were modified. Digital ABS 
plastic inserts with lock-in-groove rings were designed using SolidWorks, 3D printed, to 
hold constructs in place via a clamping mechanism. The inserts were designed to hold 
two cylindrical (cut to 3 mm diameter) carbon electrodes parallel to each other to transfer 
an electrical stimulus across the cell-seeded scaffold in each well. Flexcell Bioflex® 6-
well plates were cut for addition of a positive/negative connector for connection of 
external wires for electrical stimuli. Carbon electrodes were internally connected to the 
connector by platinum wire secured around the center of the electrode and covered with 
shrink tube and tubing with the lead soldered to a positive or negative wire. The positive 
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and negative wires from the platinum wires were soldered to the connector. Before 
ethylene oxide sterilization of the modified Flexcell Bioflex® 6-well plate, continuity 
was tested with a voltmeter. 
5.2.5 Flexcell FX-5000™ Compression System Modifications 
A FX-5000™ Compression System sold by Flexcell International Corporation 
was modified to allow for mechanical and electrical stimulation of the hCM cell seeded 
decellularized porcine myocardium scaffolds. The system purchased included a baseplate 
allowing for four Flexcell Bioflex® 6-well plates with membranes to be sealed airtight 
against it. Compressed air travelling through the baseplate served to mechanically 
stimulate cells in the wells by pushing the membrane and integrated tissue upward. 
Pressure was regulated by the main controller containing pressure regulators, transducers, 
and valves.  
To more properly model diastole and systole of the left ventricular wall, the cyclic 
pressure waveform was modelled using provided Flexcell software, at 1.17 Hz (~70 beats 
per minute) with an amplitude of 0-120-0 mmHg (350 msec duration) with a static at 0 
mmHg (450 msec duration). A pressure transducer was added to monitor real-time 
pressure applied to the silicone membrane and was acquired by a data acquisition module 
in a custom-written LabView program. Another LabView program triggered a square-
wave electrical pulse of 5V (2.78V/cm2, 20 msec-width) at the rising edge of every 
pressure wave for a coordinated pulse.  
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5.2.6 Cell Culture, Seeding and Viability   
Progenitor human cardiac myocytes (hCMs) were expanded in Dulbecco’s 
Modified Eagle Medium (DMEM), 10% Fetal Bovine Serum (FBS), and 1% 
antibiotic/antimycotic (penicillin-streptomycin). Sized, sterile, decellularized porcine 
myocardium was incubated overnight at 37 degrees Celsius in cell culture medium 
comprised of Dulbecco’s Modified Eagle’s medium (DMEM), 10% fetal bovine serum 
(FBS), and 1% antibiotic/antimycotic (penicillin-streptomycin). Before seeding, scaffolds 
were incubated 2 hours at 37°C in 6 well plates to allow removal of excess medium. 
Scaffolds were secured into two modified Flexcell Bioflex® 6-well plates (Flexcell 
International Corp., Burlington, NC, USA) and progenitor human cardiomyocytes (hCM) 
at passage 6 were aseptically injected (2 million per scaffold) and dropwise seeded (1 
million per scaffold) with a sterile 26 ½ gauge needle. Control scaffolds were not seeded 
with hCM. Both plates were placed in an incubator for 1 hour to allow for hCM 
attachment and 4 mL of cell culture media (DMEM, 10% FBS, 1% Ab/Am) was placed 
in each well. Tissue was statically cultured for 3 days before exposure to dynamic 
stimuli. Before subjecting tissue (with cells or without cells) to the electrical stimulus and 
physiological cyclic pressures (0-120-0 mmHg), preconditioning was performed at two 
days with a cyclic waveform of 0-40-0 mmHg, followed by two days of a cyclic 
waveform of 0-80-0 mmHg. Media was changed every day and 7 mL was added to each 
well to cover the dynamic tissue and account for evaporation. Static scaffolds were 
controls and media was changed every day at 4 mL per well. Cell viability was confirmed 
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with a LIVE/DEAD® Viability/Cytotoxicity kit for Mammalian Cells from Molecular 
Probes (Eugene, OR). 
5.2.7 Histological and Immunohistochemical Analysis 
Samples were fixed in 10% formalin for 48 hours, processed, paraffin-embedded, 
and sectioned to 5um. Sections were rehydrated and examined via histological staining 
with hematoxylin and eosin (H&E), Masson’s trichrome and Movat’s pentachrome. 
Manufacturer’s protocol was utilized for each stain.   
Immunohistochemistry (IHC) was performed for detection of sarcomeric α-
actinin, connexin-43, GATA-4, desmin, laminin, and collagen IV. Briefly, antigen 
retrieval was performed on rehydrated paraffin sections (5um) with heated (90-100 
degrees Celsius, 10 min) 10mM citric acid (pH=7.4). Slides were permeabilized with 
0.025% Triton X-100 for 5 minutes and then incubated in normal blocking serum for 45 
minutes. Primary antibodies (rabbit anti-sarcomeric α-actinin 2ug/mL dilution, rabbit 
anti-connexin-43 2ug/mL dilution, rabbit anti-desmin 2ug/mL dilution, rabbit anti-
GATA-4 4ug/mL dilution, rabbit anti-collagen IV 2ug/mL dilution, or rabbit anti-laminin 
4ug/mL dilution) were incubated overnight at 4 degrees Celsius. Negative controls were 
obtained by omitting the primary antibody. Endogenous peroxidases were blocked with 
0.3% hydrogen peroxide in 0.3% normal horse serum for 30 minutes. The secondary 
biotinylated anti-rabbit or anti-mouse antibody was applied for 30 minutes. Antibody 
staining was visualized using the Vector ABC peroxidase substrate kit and then lightly 
counterstained with diluted hematoxylin, before mounting. A Zeiss Axiovert 40CFL 
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microscope with AxioVision Release 4.6.3 digital imaging software (Carl Zeiss 
MicroImaging, Inc. Thornwood, NY) was utilized to obtain images. 
5.3 Results 
5.3.1 Decellularization of Porcine Myocardium Efficacy  
 To decellularized whole porcine hearts for scaffolds, a perfusion system 
previously developed within our group was employed to use the vasculature of the hearts 
to perform cellular removal (Figure 5.1).9 With this technique, three whole porcine 
hearts can be decellularized simultaneously. This decellularization platform combined 
with solutions specific to our method were seen in appearance and histological analysis 
of hematoxylin and eosin (H&E), Masson’s trichrome, and Movat’s pentachrome 
staining, to eradicate cells and residual materials (Figure 5.2). Our methods were harsh 
enough to eliminate cells, while gentle enough to retain the collagenous extracellular 
matrix, as shown in Masson’s trichrome and Movat’s pentachrome staining of fresh and 
decellularized hearts. 
5.3.2 Efficiency of Scaffold Preparation 
 By utilizing a custom 3D printed tissue slicer with integrated microtome blades, 
we were able to separate reproducible 4cm by 2cm by 2mm pieces of decellularized left 
ventricular porcine myocardium from endocardium and epicardium (Figure 5.3). 
Through our scaffold methodology of decellularization and preparation, hCM seeded on 
these scaffolds were viable at 1 hour and 3 days after seeding (Figure 5.4). Cells cultured 
statically for 21 days on these scaffolds were alive (Figure 5.8). hCM cultured for 3 days 
static, followed by 4 days dynamic conditioning, and then subjected to physiological 
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electrical and mechanical conditions for 14 days were also viable on these scaffolds 
(Figure 5.8). Few dead cells were found (images not shown). 
 
Figure 5.2: Comparison of fresh and decellularized porcine hearts. Images of hearts 
(top). Histological staining of fresh and decellularized tissue (middle to bottom) via 
hematoxylin and eosin (H&E; purple=nuclei, pink=tissue), Masson’s trichrome 
(red=muscle fibers, blue=collagen, black=nuclei) and Movat’s pentachrome 
(black=nuclei or elastic fibers, yellow=collagen or reticular fibers, blue=ground 
substance or mucin, bright red=fibrin, red=muscle). 
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Figure 5.3: Custom 3D printed tissue slicer for extraction of left ventricular myocardium 
from decellularized porcine heart. Images show isolation of decellularized myocardium 
from a piece utilizing a template (A) and tissue slicer (B) after clamping frozen tissue in 
the system (C) and cutting via secured microtome blades (D, E). The tissue slicer 
separated the heart wall into endocardium (F), myocardium (G), and epicardium (H). 
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5.3.3 Investigation of Modified Flexcell FX-5000™ Compression System and Plates 
 By modifying a Flexcell FX-5000™ compression system and Flexcell Bioflex® 
6-well plates with membranes, we were able design a platform for electrical and 
mechanical stimulation of tissue seeded with hCM. 3D printed ABS well plate inserts 
were sturdy for the experimental duration under dynamic and static conditions. These 
inserts were able to securely hold the tissue in place for 18 days, as well as provide 
housing for carbon electrodes and wiring after cutting excess plastic from the plates 
(Figure 5.5). The baseplate of this system holding the altered well plates was able to be 
contained within a standard cell culture incubator with room to spare (Figure 5.6). 
Additional programs written in LabVIEW to provide electrical stimulus and examine 
pressure exerted on the tissue were able to be run on the computer purchased with the 
system. Modelling of the electrical pulse between electrodes in COMSOL confirmed 
current handling in this system (Figure 5.6). By utilizing a ramping up regimen for 
dynamic tissue before physiological conditions, as illustrated in Figure 5.7, this system 
supported hCM for 14 days in this state (Figure 5.8).  
5.3.4 Cellular Analysis 
There was high cell viability after the duration of the experiment in both the 
dynamic and static groups seeded with hCM (Figure 5.8). Cells were aligned and found 
throughout the tissue in the dynamic group, while cells in the static group were spherical 
and not aligned. Few dead cells were found (images not shown). Hematoxylin and eosin 
(H&E) staining of both groups showed hCM on the surface and within the scaffold. As 
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seen in Figure 5.9, cells in dynamic and static scaffolds stained positive for 
cardiomyocyte markers such as connexin-43, sarcomeric α-actinin, desmin, and GATA-4. 
5.3.5 Extracellular Matrix Investigation 
When investigating scaffolds that were dynamically and statically conditioned, 
with or without cells, it was found that samples from all groups all had collagen IV 
present, with muscle fibers and elastin ﬁbers missing (Figure 5.10, Figure 5.11). 
Scaffolds seeded with hCM stained for nuclei. As visualized by immunohistochemistry 
(IHC) staining in Figure 5.10, laminin presence was more noticeable in scaffolds seeded 
with cells, when compared to those without cells. 
 
 
Figure 5.4: Viability of human cardiomyocytes (hCM) after seeding. Live images show 
viable (green) hCM after 1 hour (left) and 3 days (right) of static seeding. 
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Figure 5.5: Modifications of Flexcell plates and mounting prepared tissue. Uncoated 
Flexcell plates cut for insertion of connector (A) for positive and negative wires (C) to 
deliver stimulus to electrodes (D). 3D printed tissue holding inserts (F) hold tissue via a 
clamping ring (E). All components (B) assembled with tissue (G) and cells are ready for 
the modified Flexcell system. 
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Figure 5.6: Flexcell setup and monitor. A diagram illustrating the modified Flexcell 
setup (A) shows addition of data acquisition (DAQ) devices for monitoring pressure and 
delivering electrical stimulus included with the Flexcell controller, monitor, and baseplate 
holding modified well plates. An incubator (B) houses the modified well plates clamped 
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to the baseplate (C). The system is controlled via a computer and monitor (D) utilizing 
Flexcell software to deliver air to the baseplate and an original LabVIEW program to 
deliver an electrical stimulus to the tissue. The baseplate can hold up to four well plates 
(E). 5 volts travel between the electrodes as shown by COMSOL modelling (F). 
 
Figure 5.7: Workflow of experimental set-up for dynamic and static tissues. Tissue was 
preconditioned in the dynamic system for 4 days before electrical stimulus and exposure 
to normal native cyclic pressure of a 120mmHg. 
 123 
 
Figure 5.8: Cellular viability and presence in dynamic and static conditions. Live assay 
of decellularized porcine myocardium cultured with hCM after 18 days static culture (A) 
and 18 days of dynamic culture on side (B), inside (C), and other side (D) of the tissue. 
Green= live cells. Hematoxylin and eosin staining of cells (purple) show presence in 
tissue (pink) after 18 days of static (E) or dynamic (F) culture. 
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Figure 5.9: Cellular analysis of human cardiomyocytes (hCM) in static and dynamic 
conditions. Immunohistochemical (IHC) staining of cardiomyocyte markers after 18 days 
of static and dynamic culture highlight connexin-43 (CX-43), sarcomeric alpha-actinin 
(Sarc. α-actinin), desmin, and GATA-4. (brown=positive; purple=tissue; inserts=negative 
controls) 
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Figure 5.10: Collagen IV and laminin extracellular matrix analysis on scaffolds 
subjected to static and dynamic conditions with and without human cardiomyocytes 
(hCM). Immunohistochemical (IHC) staining of collagen IV and laminin in groups. 
(brown=positive; purple=tissue; inserts= negative controls) 
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Figure 5.11: Extracellular matrix investigation of static and dynamic scaffolds with and 
without human cardiomyocytes (hCM). Masson’s trichrome (red=muscle fibers, 
blue=collagen, black=nuclei) and Movat’s pentachrome (black=nuclei or elastic fibers, 
yellow=collagen or reticular fibers, blue=ground substance or mucin, bright red=fibrin, 
red=muscle) staining. 
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5.4 Discussion 
 Cardiac tissue engineering has emerged as a promising solution for a functional 
tissue replacement for patients who have experienced a myocardial infarction, which 
causes myocardial ischemia. Preconditioning is important in developing an engineered 
tissue that is mature and behaves properly when implanted.10 Electrical and mechanical 
stimuli have been proven to be pivotal in this. Currently, combinational 
electromechanical bioreactors have only tested animal cells encapsulated in gels at low 
cyclic stretch or seeded in decellularized tissue for a short amount of time.56 Though, 
many discrepancies exist between animal and human CMs, physiological conditions 
could destroy weak gels, and these platforms support small tissues, limiting their 
translation to human patients.7,8  
 To fill this disparity, we developed a physiologically relevant bioreactor that was 
able to subject larger (4cm by 2cm by 2mm) and mechanically sound scaffolds with 
human cells. Within our lab we have produced a complex 3D acellular scaffold from 
decellularized porcine myocardium, which has been proven to retain mechanical and 
vascular integrity, and important ECM basal lamina components crucial to recapitulating 
native myocardium, such as fibronectin, laminin, and collagen IV.9 Myocardial ECM is 
very diverse and this specific environment is essential for inherent cellular interactions 
and tethering.11,12 By designing a tissue slicer we were able to simply and reproducibly 
extract myocardium from our scaffold at around a 2mm thickness.   
For our cells we decided to employ primary hCM progenitor cells. They have 
recently been used for research in areas such as cardiotoxicity, therapeutic testing, 
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scaffold biocompatibility, and the study of pathways involved in oxidative stress.13–16 
These cells are more cost effective than induced pluripotent stem cells (iPSCs), can 
proliferate, and express cardiac markers, such as sarcomeric α-actin, making them ideal 
for our research.17  
 We were able to create tissue engineered myocardium my combining hCM and 
our scaffold. This myocardium was supported in our electromechanical bioreactor for 14 
days at physiologically relevant conditions with mechanical and electrical stimuli after an 
initial ramping up period in order to acclimate the hCM to this highly dynamic 
environment. Not only was this system able to maintain viable cells for 14 days, but 
dynamic scaffolds had live hCM throughout the tissue and on both surfaces that were 
aligned, while statically cultured tissue engineered myocardium had spherical cells 
localized to one surface. Morphologically, our dynamic myocardium is more similar to 
cellular alignment of native myocardium and with this system we can support these cells 
within our 2mm thick tissues. 
 CM markers were evaluated as a checkpoint to determine if our electromechanical 
bioreactor allowed for the preservation of the CM phenotype in our scaffolds. To do so 
we investigated connexin 43, sarcomeric α-actinin, desmin, and GATA-4 in dynamic and 
static conditions. Connexin 43 or gap junction protein, plays a key role in synchronous 
cellular contraction and the exchange of molecules, such as calcium, between cells.18,19 
Sarcomeric α-actinin and desmin are integral parts of the sarcomere in CMs and 
contribute to its contraction and overall functionality.19–21 GATA-4 is crucial for CM 
development, differentiation, as it is only expressed by CMs and is a transcriptional 
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regulator for cardiac genes.16,19 These proteins were all found to be expressed by hCM in 
scaffolds cultured in dynamic or static conditions. 
 Our scaffold was also inspected with and without cells to determine if our 
dynamic conditioning would adversely alter the ECM, as it could compromise overall 
function of our tissue engineered myocardium. Scaffolds were not adversely altered in 
the course of 14 days within the electromechanical bioreactor. All scaffolds dynamically 
and statically conditioned, with and without cells, were shown to retain collagen IV and 
laminin, important ECM proteins. Collagen IV provides the supportive framework for the 
ECM and cells to interact.22 Laminins are glycoproteins located mainly in the basal 
lamina and are vital for cell-ECM attachment, cell differentiation, survival, and 
migration.23 Dynamic and static scaffolds with cells had increased expression of laminin 
compared to scaffolds without cells, which is promising. This shows the hCM are 
integrating and interacting with the ECM, by connecting to and secreting their own 
matrix proteins.  
5.5 Conclusions 
 Tremendous strides have been made in cardiac tissue engineering, with even more 
to come. We are the first to our knowledge to subject acellular porcine scaffolds seeded 
with hCM to physiological electromechanical conditions for 14 days. We found that 
dynamic tissues had cellular alignment and cells throughout the tissue, while static tissue 
did not. This bioreactor system for myocardium was able to support human cells 
expressing cardiomyocyte markers for 14 days at physiological conditions, without 
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altering the ECM. This platform has great potential for myocardial tissue preconditioning 
and could be useful for disease modeling.  
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CHAPTER 6: TISSUE ENGINEERING MODELS OF DIABETIC CARDIAC 
PATHOLOGY 
 
6.1 Introduction  
There is no cure for DCMP, except for heart transplantation which has a very long wait 
list.1 Treatment for this disease is lumped in with other cardiomyopathies and heart 
failure, however these therapies only treat the symptoms and downstream complications 
that accompany heart failure without addressing origins of the problem.2 As DCMP 
progresses, significant changes are seen in heart mass, size and wall thickness, in 
conjunction with abnormal diastolic and/or systolic function.3 Patients at the end stage of 
DCMP experience symptoms associated with heart failure, such as shortness of breath, 
fluid retention, dizziness, and coughing.4 Patients with heart failure have a 5-year 
mortality of approximately 50%.1 
Understanding the underlying mechanisms in the early stages of DCMP are crucial for 
diagnosis and targeted therapies early on. As of now, knowledge of this disease has relied 
on rodent models, cell culture models, and cadaveric human patient hearts.5,6  Human 
cadaveric hearts with DCMP have been excellent for elucidating end stage cellular and 
extracellular changes and rodent and cell culture models have been utilized to fill in the 
gaps. Problems arise within rodent models as they have varying progressions of diabetes, 
circulating lipid concentrations, cardiomyocyte electrophysiological properties, higher 
beats per minute, and inflammatory responses when compared to human diabetic 
patients.7–9 Human cells have been studied to investigate specific cell type alterations 
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associated with the diabetic environment, however this is an oversimplified 2D static 
environment, lacking an extracellular matrix (ECM).10  
Tissue engineering holds much promise in bridging this gap. 3D organotypic tissue 
engineered models allow for studies of individual cell types in a dynamic, controllable 
and repetitive environment.11 Other research groups have tried to fill this need but have 
failed to either produce a complex and dynamic 3D ECM environment or have examined 
animal cells, instead of human cells.12,13 We hypothesized that if we combined human 
cardiomyocytes (hCMs) and an acellular porcine myocardium scaffold within (1) a 
perfusion 3D Kube minibioreactor or (2) an electromechanical bioreactor supplemented 
with high glucose, that we would be able to detect early alterations associated with 
DCMP. These platforms could be useful for determining and testing targeted 
therapeutics, as well as markers for prompt diagnosis of DCMP in diabetic patients. 
6.2 Materials and Methods 
6.2.1 Materials 
Primary human cardiac myocytes (hCM) were from Promocell GmbH (Heidelberg, 
Germany). Dulbecco’s Modified Eagle Medium (DMEM) and antibiotic/antimycotic 
were from Corning Incorporated (Oneonta, NY). Fetal Bovine Serum (FBS) was from 
Atlanta Biologicals (Atlanta, GA). 3D Kubes were purchased from Kiyatec (Greenville, 
SC). A multichannel peristaltic pump was from Cole-Parmer (Vernon Hills, IL). A FX-
5000™ Compression System and Bioflex® 6-well plates were from Flexcell 
International Corp. (Burlington, NC, USA). Carbon electrodes were from Alfa Aesar 
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(Haverhill, MA). Platinum wire was purchased from Ladd Research Industries (Williston, 
VT). Bicinchoninic acid protein assay was from Pierce Biotech (Rockford, IL). 
Electrophoresis apparatus, gel imager and imaging software, chemicals, and molecular 
weight standards were from Bio-rad (Hercules, CA). Clean-BlotTM IP Western Blot 
Detection kit was obtained from Thermo Fisher Scientific Inc. (Waltham, MA). The 
Vectastain Elite kit, ABC diaminobenzidine tetrahydrochlorine peroxidase substrate kit, 
and Vectashield mounting medium were from Vector Laboratories (Burlingame, CA). 
The following antibodies were used: rabbit anti-superoxide dismutase-2 (Abcam, 
ab13534), rabbit anti-advanced glycation endproducts (Abcam, ab23722), rabbit anti-
light chain 3B (Abcam, ab48394), rabbit anti-caspase-3 (Millipore, 06-735 and Thermo 
Fisher, MA1-16843), mouse anti-N-epsilon-(carboxylmethyl)lysine (R&D Systems, 
MAB3247), rabbit anti-inositol-requiring enzyme 1 (Abcam, ab48187), and rabbit anti-
protein kinase RNA-like endoplasmic reticulum kinase (Abcam, ab192591). Biotinylated 
anti-rabbit IgG and anti-mouse IgG were purchased from Vector Laboratories 
(Burlingame, CA). Movat’s Pentachrome Kit and Masson’s Trichrome Kit were from 
Poly Scientific (Bay Shore, NY). All other chemicals were of the highest purity and 
purchased from Sigma-Aldrich Corporation (Lakewood, NJ). 
6.2.2 Decellularization of Porcine Myocardium Scaffold 
Whole, healthy, porcine hearts were obtained from a local slaughterhouse and 
decellularized utilizing a previously published method (see Chapter 5).14 Briefly, 
pulmonary veins were cannulated, excess adipose and connective tissue were cleaned 
from the aorta, aortic leaflets were removed, and aorta was connected to a perfusion 
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decellularization system. Decellularization was performed with 1% sodium dodecyl 
sulfate (SDS) solution changes and a DNAse/RNase treatment. Washes of distilled 
deionized water (ddH2O) and PBS were used for cleaning. Scaffolds were stored in PBS 
with 0.02% sodium azide and 0.001% protease inhibitor cocktail (Sigma) at 4 degrees 
Celsius until tissue bioreactor use in either the 3D Kube minibioreactor or modified 
electromechanical Flexcell bioreactor. 
6.2.3 Tissue Preparation and Sterilization  
For the 3D Kube minibioreactor, decellularized porcine myocardium scaffolds were 
removed using a 5mm round biopsy punch. For the electromechanical bioreactor, 
decellularized porcine myocardium was extracted from the left ventricle was sliced to 
2mm by 4cm by 2 cm via a specialized tissue slicer (see Chapter 5). Briefly, the scaffold 
was cut into 4 cm by 2 cm pieces using a 3D printed template, frozen at 20 degrees 
Celsius, then cut into 2 mm slices with a custom designed 3D printed tissue slicer.  
After isolation, the scaffolds were washed in three rinses of PBS (30 min, 2 hr, 30 min) 
and then sterilized in sterile 0.01% peracetic acid in PBS for 2 hours. Excess peracetic 
acid was removed through three washes of sterile PBS (30 min, 2hr, 30 min). Scaffolds 
were stored in sterile PBS at 4 degrees Celsius until cell seeding preparation. 
6.2.4 Adaptation of Well Plates and FX-5000™ Compression System Modifications 
To accommodate cell-seeded scaffolds and an electrical stimulus like physiological 
conditions, Flexcell Bioflex® 6-well plates were modified as previously described (see 
Chapter 5). Briefly, inserts were designed to hold constructs in place and to hold two 
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wired carbon electrodes parallel to each other to transfer an electrical stimulus across the 
cell-seeded scaffold in each well. Flexcell Bioflex® 6-well plates were cut for addition of 
a positive/negative connector for connection of external wires and electrodes were 
bridged with platinum wires for electrical stimuli. Continuity was tested with a voltmeter 
and plates were sterilized with ethylene oxide. 
A FX-5000™ Compression System sold by Flexcell International Corporation was 
modified to allow for mechanical and electrical stimulation of the hCM cell seeded 
decellularized porcine myocardium scaffolds (see Chapter 5). The cyclic pressure 
waveform to mimic diastole and systole of the left ventricular wall was modelled using 
provided Flexcell software, at 1.17 Hz (~70 beats per minute) with an amplitude of 0-
120-0 mmHg (350 msec duration) with a static at 0 mmHg (450 msec duration). This was 
confirmed with the addition of a pressure transducer and a data acquisition module in a 
custom-written LabView program. Another LabView program triggered a square-wave 
electrical pulse of 5V (2.78V/cm2, 20 msec-width) at the rising edge of every pressure 
wave for a coordinated pulse.  
6.2.5 Cell Culture and Expansion 
Progenitor human cardiac myocytes (hCMs) were expanded in normal glucose. They 
were then cultured for 14 days in normal glucose or high glucose media before seeding 
on prepared and sterilized decellularized porcine myocardial scaffolds. Normal and high 
glucose media constituted of Dulbecco’s Modified Eagle Medium (DMEM), 10% Fetal 
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Bovine Serum (FBS), and 1% antibiotic/antimycotic (penicillin-streptomycin), with 5mM 
(1g/L) and 25mM (4.5g/L) glucose, respectively.  
6.2.6 3D Kube Minibioreactor Setup  
For the 3D Kube minibioreactor systems, sterile scaffolds were then placed in normal 
glucose media constituted of DMEM, 10% FBS, and 1% antibiotic/antimycotic 
(penicillin-streptomycin) overnight at 37 degrees Celsius. The next day, these scaffolds 
were injected with a 26½ gauge needle aseptically with hCM with 200,000 cells per 
scaffold. After 48 hours of static resting in either normal (n=11) or high (n=10) glucose 
media, two bioreactors (one normal and one with high glucose media) were aseptically 
assembled utilizing 3D Kubes to house the respective reseeded scaffolds. The bioreactors 
were housed in an incubator (37°C, 5% CO2). A multi-channel peristaltic pump provided 
a flow rate of 1mL/min from a fluid reservoir. 1% antibiotic/antimycotic was injected 
every 3.5 days into the closed system to replenish degraded antibiotics and media was 
changed every week for each bioreactor. The scaffolds were subjected to these conditions 
for 14 days then analyzed (Table 6.1). Cell viability was confirmed with a 
LIVE/DEAD® Viability/Cytotoxicity kit for Mammalian Cells from Molecular Probes 
(Eugene, OR). 
Conditions # Samples: Protein # Samples: Histology # Samples: Live/Dead # Samples: Cryosections
Normal Glucose 6 2 1 1
High Glucose 6 2 1 1
3D Kube Minibioreactor
 
Table 6.1: Sample size and analysis for 3D Kube minibioreactor. 
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6.2.7 Electromechanical Bioreactor Setup 
Sized, sterile, decellularized porcine myocardium was incubated overnight at 37 degrees 
Celsius in cell culture medium comprised of Dulbecco’s Modified Eagle’s medium 
(DMEM), 10% fetal bovine serum (FBS), and 1% antibiotic/antimycotic (penicillin-
streptomycin). Before seeding, scaffolds were incubated 2 hours at 37°C in 6 well plates 
to allow removal of excess medium. Scaffolds were secured into two modified Flexcell 
Bioflex® 6-well plates (Flexcell International Corp., Burlington, NC, USA) and 
progenitor human cardiomyocytes (hCM) at passage 6 were aseptically injected and 
dropwise seeded (2 million per scaffold) with a sterile 26 ½ gauge needle. Plates were 
placed in an incubator for 1 hour to allow for hCM attachment and then 4 mL of cell 
culture media (normal or high glucose, depending on expansion conditions) was added to 
each well. Tissue was statically cultured for 3 days before subjecting tissue cultured in 
either normal or high glucose to preconditioning in the bioreactor. Preconditioning was 
performed with a cyclic waveform of 0-40-0 mmHg for two days, followed by two days 
with a cyclic waveform of 0-80-0 mmHg, and then tissue engineered myocardium was 
subjected to 0-120-0 mmHg cyclic waveform with electrical stimuli for 14 days. Normal 
and high glucose media was changed every day and 7 mL was added to each well to 
cover the dynamic tissue and account for evaporation. Cell viability was confirmed with a 
LIVE/DEAD® Viability/Cytotoxicity kit for Mammalian Cells from Molecular Probes 
(Eugene, OR). Samples were divided and processed for analysis (Table 6.2, Figure 6.1). 
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Conditions # Samples: Protein, RNA, and Histology # Samples: Live/Dead, Cryosections
Normal Glucose 11 1
High Glucose 11 1
Electromechanical Bioreactor 
 
Table 6.2: Sample size and analysis for electromechanical bioreactor.  
 
Figure 6.1: Division of electromechanical scaffolds for analysis. 
6.2.8 Histological Analysis 
After 14 days in either the 3D Kube minibioreactor or electromechanical bioreactor, 
normal and high glucose samples were fixed in 10% formalin for 48 hours and 
histologically processed, paraffin embedded, and sectioned on slides. Rehydrated paraffin 
sections (5um) were stained with hematoxylin and eosin (H&E), Movat’s pentachrome, 
and Masson’s trichrome kits for normal and high glucose samples. Manufacturer’s 
guidelines were followed for these.  
 Immunohistochemistry (IHC) was performed for detection of superoxide 
dismutase-2 (SOD-2), light chain 3B (LC3B), carboxymethyl lysine (CML), inositol-
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requiring enzyme 1 (IRE-1) and caspase-3 to compare high and normal glucose samples. 
Briefly, antigen retrieval was performed on rehydrated paraffin sections (5um) with 
heated (90-100 degrees C, 10 min) 10mM citric acid (pH=7.4). Slides were 
permeabilized with 0.025% Triton X-100 for 5 minutes and then incubated in normal 
blocking serum for 45 minutes. Primary antibodies (rabbit anti-SOD-2 1ug/mL dilution, 
rabbit anti-LC3B 5ug/mL dilution, rabbit anti-IRE-1 4ug/mL, mouse anti-CML 2ug/mL, 
or rabbit anti-caspase-3 4ug/mL dilution) were incubated overnight at 4 degrees Celsius. 
Negative controls were obtained by omitting the primary antibody. Endogenous 
peroxidases were blocked with 0.3% hydrogen peroxide in 0.3% normal horse serum for 
30 minutes. The secondary biotinylated anti-rabbit antibody was applied for 30 minutes. 
Antibody staining was visualized using the Vector ABC peroxidase substrate kit and then 
lightly counterstained with diluted hematoxylin, before mounting. A Zeiss Axiovert 
40CFL microscope with AxioVision Release 4.6.3 digital imaging software (Carl Zeiss 
MicroImaging, Inc. Thornwood, NY) was utilized to obtain images. 
6.2.9 Lipid Staining  
Lipid accumulation was visualized in both bioreactor system samples via oil red O on 
cryosectioned normal and high glucose samples. Slides were fixed in 4% 
paraformaldehyde, rinsed in distilled, deionized water (ddH2O), rinsed in 60% 
isopropanol, and stained in 0.3% Oil Red O in isopropanol solution. Slides were then 
rinsed twice in 60% isopropanol, stained in a 1 to 1 hematoxylin in ddH2O solution, 
rinsed in ddH2O, and mounted with aqueous Vectashield mounting medium. Light 
images were taken on a Zeiss Axiovert 40CFL microscope, as described before. 
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6.2.10 Detection of Caspase-3, SOD-2, CML, AGE, LC3B, and PERK 
Western blotting was employed to compare amounts of caspase-3, SOD-2, CML, 
advanced glycation endproducts (AGEs), LC3B, and protein kinase RNA-like 
endoplasmic reticulum kinase (PERK) between normal glucose and high glucose 
conditioned samples run in the electromechanical bioreactor for 14 days. Proteins were 
extracted by radioimmunoprecipitation assay (RIPA) extraction buffer (50mM Tris-HCl 
pH 7.4, 150mM sodium chloride (NaCl), 1mM ethylenediaminetetraacetic acid (EDTA), 
1% Triton X-100, 1% Sodium Deoxycholate, 0.1% sodium dodecyl sulfate (SDS), with 
protease inhibitor cocktail). Protein concentrations in the samples were found using a 
bicinchoninic acid protein (BCA) assay. For each sample, 20ug of protein per lane was 
loaded and a pre-stained molecular weight standard was loaded in one of the lanes. 
Protein from the gels were transferred to polyvinylidine fluoride membranes. Primary 
antibodies (mouse anti-caspase-3 1ug/mL, rabbit anti-SOD-2 1ug/mL, mouse anti-CML 
1ug/mL, rabbit anti-AGE 1ug/mL, rabbit anti-LC3B 1ug/mL, or rabbit anti-PERK 
1ug/mL) were applied overnight at 4°C. The secondary antibody from the anti-
mouse/rabbit kit was then applied for 45 minutes at room temperature. The 
polyvinylidine fluoride membranes were fluorescently tagged with detection solution 
from the anti-mouse/rabbit kit (1 minute) and then imaged using the Chemi-Doc™ XRS+ 
system from Bio-rad (Hercules, CA). Relative band intensities were determined using 
Bio-rad Image Lab Software Version 5.1, beta build 1 and values were analyzed. 
 Relative amounts of caspase-3 between groups in the electromechanical 
bioreactor were examined with the ApoTarget Caspase-3 / CPP32 Colorimetric Protease 
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Assay from Invitrogen (Carlsbad, CA). Manufacturer’s protocol was followed. Total 
protein was measured via a BCA assay and 100ug was used per sample (n=5 per group). 
Intensities were measured using the Synergy H1 Hybrid Reader System from BioTek 
(Winooski, VT). 
6.2.11 Matrix Metalloproteinase Activity Analysis 
Matrix Metalloproteinase (MMP) activity in high and normal glucose media and tissue 
protein lysates were analyzed by gelatin zymography. For media analysis, 10uL of 
normal or high glucose media per sample was loaded into a gelatin zymography gel with 
1x sample buffer. For protein lysate analysis, 20ug of protein was loaded. A pre-stained 
molecular weight standard was loaded into a separate lane for each gel. After 
electrophoresis separation, the zymography gel was washed in a triton-X solution and 
MMPs were activated with a brij-35 development buffer for 24 hours at 37 degrees 
Celsius. After staining with Coomassie and destaining, MMP clear bands were imaged 
using the Chemi-Doc™ XRS+ system and evaluated by densitometry using the using 
Bio-rad Image Lab Software. 
6.2.12 Statistical Analysis 
 Results are expressed at mean ± standard deviation (SD). Statistical analysis was 
performed between groups utilizing Welch’s two-tailed t-test in excel. Significance was 
determined with an alpha (α) value of 0.05. 
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6.3 Results 
6.3.1 3D Kube Minibioreactor Results 
6.3.1.1 Analysis of Cell Seeding and Viability in 3D Kube Minibioreactor 
 Constructs were placed in either a high or normal glucose 3D Kube 
minibioreactor under perfusion conditions in an incubator (Figure 6.2). Before placing 
hCM seeded scaffolds into the 3D Kube minibioreactor, analysis of cell viability was 
performed after sitting statically for 48 hours to allow for hCM attachment. As seen in 
Figure 6.3, hCMs seeded in the scaffold were viable at 48 hours after injection. Scaffolds 
from both high and normal glucose dynamically conditioned in the 3D Kube 
minibioreactor for 14 days had live cells (Figure 6.3). As revealed in Figure 6.4, 
hematoxylin and eosin (H&E) staining of these samples after conditioning showed hCM 
within the decellularized porcine myocardium scaffolds. 
6.3.1.2 Investigation of Matrix Metalloproteinase Activity and AGEs 
 Matrix metalloproteinase (MMP) activity and advanced glycation endproduct 
(AGE) formation within high and normal glucose 3D Kube minibioreactor samples were 
determined with a gelatin zymography and protein western blotting analysis, respectively. 
As shown in Figure 6.5, there were no significant differences between groups in overall 
MMP, MMP9, and MMP2 activity. Protein analysis of AGEs revealed no significant 
differences between the two groups (Figure 6.6). 
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Figure 6.2: Set-Up of 3D Kube minibioreactor. (A) Minibioreactor was housed in incubator. (B) 
Diagram illustrating media flow in the system. (C) 3D Kube minibioreactor platform fully 
assembled with tubing, manifolds, reservoir, and 3D Kubes housing seeded constructs. 
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Figure 6.3: Viability analysis of hCM seeded on decellularized porcine myocardium scaffolds. 
Static seeding after 48 hours (top), and dynamic minibioreactor conditioned normal (middle) and 
high (bottom) glucose after 14 days. (green=live cells, red=dead cells). 
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Figure 6.4: Hematoxylin and eosin (H&E) staining of samples after 14 days in 3D Kube 
minibioreactor. Normal (left) and high (right) glucose showed cells (purple) and tissue (pink).  
6.3.1.3 Antioxidant Defenses and Lipid Accumulation 
 Antioxidant defense mechanisms were investigated with immunohistochemical 
(IHC) staining and western blotting for protein analysis. Superoxide dismutase 2 (SOD-
2), an endogenous antioxidant defense mechanism, was shown to be present in both high 
and normal glucose samples stained via IHC (Figure 6.7). SOD-2 had an upward trend in 
the high glucose group as seen in western blotting. Lipid accumulation was visualized 
with staining and was only found in high glucose samples (Figure 6.8). 
6.3.1.4 Examination of Apoptosis and Autophagy  
Caspase-3 was employed to determine programed death or apoptosis within samples. 
This protein was present in both normal and high glucose conditioned groups, as seen 
with IHC staining (Figure 6.9). IHC staining of samples for light chain 3B (LC3B), an 
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autophagic marker, revealed its presence in both groups (Figure 6.10). Western blotting 
analysis showed significantly higher expression of LC3B in the high glucose group.  
 
Figure 6.5: Overall matrix metalloproteinase (MMP), MMP9, and MMP2 activity in 3D Kube 
normal and high glucose media via gelatin zymography. RDU= relative densitometry units. 
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Figure 6.6: Detection of advanced glycation endproducts (AGEs) in 3D Kube minibioreactor 
samples by employing western blotting. RDU= relative densitometry units. 
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Figure 6.7: Investigation of antioxidant superoxide dismutase 2 (SOD-2) in 3D Kube normal and 
high glucose groups. (A) Immunohistochemical (IHC) staining of samples for SOD-2 
visualization. (brown=positive, dark purple=nuclei; inserts=negative controls) (B) SOD-2 protein 
western blotting analysis of the two groups. RDU= relative densitometry units.   
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Figure 6.8: Staining for lipid accumulation in normal and high glucose samples. Red= lipids. 
 
 
Figure 6.9: Visualization of apoptosis marker caspase-3 in normal and high glucose 3D Kube 
minibioreactor samples via immunohistochemistry (IHC). (brown=positive, dark purple=nuclei; 
inserts=negative controls). 
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Figure 6.10: Inquiry of light chain 3B (LC3B), a marker of autophagy, between 3D Kube groups. 
(A) Immunohistochemical (IHC) staining of samples for LC3B. (brown=positive, dark 
purple=nuclei; inserts=negative controls) (B) Western blotting analysis of LC3B in groups. 
RDU= relative densitometry units.  * indicates statistical difference. 
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6.3.2 Electromechanical Bioreactor Results 
6.3.2.1 Analysis of Cell Seeding and Viability in Electromechanical Bioreactor 
 Before mounting into the electromechanical bioreactor, we determined that hCM 
seeded on decellularized porcine myocardium were viable after one hour and three days 
after static seeding (Figure 6.11). After 14 days under dynamic conditions, engineered 
tissues contained live cells in both normal and high glucose conditions (Figure 6.12). 
Trichrome and pentachrome staining both showed hCM integrated within the collagen 
ECM scaffold (Figure 6.13).  
6.3.1.2 Investigation of Matrix Metalloproteinase Activity and AGEs 
 MMP activity and accumulation of AGEs were examined in electromechanically 
stimulated normal and high glucose conditioned engineered tissues and media. When 
investigating MMP activity in media samples, there were no differences found between 
the two groups for overall MMP, MMP9 and MMP2 activity (Figure 6.14). MMP 
activity in tissue lysates showed no significant difference in overall MMP, MMP9, and 
active MMP2, with significantly higher pro MMP2 and overall MMP2 in high glucose 
conditions, as seen in Figure 6.15. Carboxymethyl lysine (CML), an AGE, was shown to 
be present in both groups with IHC staining and slightly greater in the high glucose group 
with western blot analysis (Figure 6.16). Western blotting for AGE detection indicated 
comparable amounts in both groups. 
 
 153 
 
Figure 6.11: Viability of human cardiomyocytes (hCM) after seeding. Live images show viable 
(green) hCM after 1 hour (left) and 3 days (right) of static seeding. 
 
Figure 6.12: Cellular viability after 14 days of electromechanical stimuli in normal and high 
glucose conditions. Green= live cells. 
6.3.1.3 Examination of Cellular Antioxidant Defenses, Autophagy, and Apoptosis 
 Cellular changes known as DCMP hallmarks were studied such as antioxidant 
defense mechanisms, autophagy, and apoptosis. Superoxide dismutase 2 (SOD-2), an 
endogenous antioxidant, was visible in both normal and high glucose bioreactor samples 
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with IHC staining (Figure 6.17). SOD-2 protein detection with western blotting revealed 
a greater inclination in high glucose samples. IHC staining and western blotting of light 
chain 3B (LC3B), an autophagy protein, indicated similar amounts in each group (Figure 
6.18). Caspase-3, an apoptosis marker, stained in both groups (Figure 6.19). Protein 
analysis of caspase-3 revealed an upward trend in high glucose samples with western 
blotting and similar expression in both with a caspase-3 assay. 
 
Figure 6.13: Cell and ECM visualization in electromechanical normal and high glucose samples. 
Masson’s trichrome (red=muscle fibers, blue=collagen, black=nuclei) and Movat’s pentachrome 
(black=nuclei or elastic fibers, yellow=collagen or reticular fibers, blue=ground substance or 
mucin, bright red=fibrin, red=muscle) staining of groups from normal and high glucose 
conditions. 
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Figure 6.14: Matrix metalloproteinase (MMP) activity in media from electromechanically 
conditioned normal and high glucose samples via gelatin zymography. MMP activity results for 
all MMPs, MMP9, and MMP2 in media.  RDU= relative densitometry units. 
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Figure 6.15: Matrix metalloproteinase (MMP) activity in tissue lysates from electromechanically 
conditioned normal and high glucose samples via gelatin zymography. MMP activity results for 
all MMPs, MMP9, MMP2, proMMP2, and activeMMP2 in tissue. RDU= relative densitometry 
units. * indicates statistically significant difference. 
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Figure 6.16: Investigation of advanced glycation endproducts (AGEs) in normal and high 
glucose groups electromechanically stimulated. (A) Immunohistochemical (IHC) staining of 
samples for carboxymethyl lysine (CML), an AGE. (brown=positive, dark purple=nuclei; 
inserts=negative controls) (B) Western blotting analysis of CML in groups. (C) Western blotting 
analysis for AGE in samples. RDU= relative densitometry units.   
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Figure 6.17: Examination of antioxidant superoxide dismutase 2 (SOD-2) in electromechanical 
bioreactor normal and high glucose groups. (A) Immunohistochemical (IHC) staining of samples 
for SOD-2 visualization. (brown=positive, dark purple=nuclei; inserts=negative controls) (B) 
SOD-2 protein western blotting analysis of the two groups. RDU= relative densitometry units. 
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Figure 6.18: Inquiry of light chain 3B (LC3B), a marker of autophagy, between 
electromechanical bioreactor groups. (A) Immunohistochemical (IHC) staining of samples for 
LC3B. (brown=positive, dark purple=nuclei; inserts=negative controls) (B) Western blotting 
analysis of LC3B in groups. RDU= relative densitometry units.   
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Figure 6.19: Analysis of apoptosis marker, caspase-3, in electromechanically conditioned normal 
and high glucose groups. (A) Immunohistochemical (IHC) staining of samples for caspase-3 
visualization. (brown=positive, dark purple=nuclei; inserts=negative controls) (B) Caspase-3 
protein western blotting analysis of the two groups. RDU= relative densitometry units. (C) 
Results from ApoTarget caspase-3 assay. 
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Figure 6.20: Endoplasmic reticulum (ER) stress inspection in normal and high glucose 
electromechanical samples. (A) Immunohistochemical (IHC) staining of inositol requiring 
enzyme-1 (IRE-1) in samples. (brown=positive, dark purple=nuclei; inserts=negative controls) 
(B) Western blotting of protein kinase RNA-like ER kinase (PERK) in the two groups. RDU= 
relative densitometry units.  
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Figure 6.21: Staining for lipid accumulation in electromechanical bioreactor normal and high 
glucose samples. Red= lipids. 
6.3.2.4 Endoplasmic Reticulum Stress and Lipid Accumulation 
 Evaluation of endoplasmic reticulum (ER) stress and lipid accumulation was 
performed, as they are traits of DCMP.  IHC staining of inositol requiring enzyme-1 
(IRE-1), an ER stress marker, showed existence in both normal and high glucose 
conditions (Figure 6.20). Western blotting of another ER stress protein, protein kinase 
RNA-like ER kinase (PERK) showed no difference between groups. Oil red O staining 
revealed lipids within normal and high glucose samples, with more accrual in high 
glucose conditions (Figure 6.21). 
6.4 Discussion 
 DCMP is diagnosed once symptoms, including but not limited to, shortness of 
breath, angina, and fluid retention, are present in the patient.15 Currently, no cure exists 
for DCMP and its treatment is grouped with other heart failures.16 To diagnose and treat 
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or even reverse early stages of this disease, understanding the underlying mechanisms of 
its progression is key. As of now, animal models and cell cultures have been utilized to 
elucidate these initial changes.5 However, there are discrepancies that exist between 
rodent models and human patients, such as differing heart beats per minute, circulating 
lipid concentrations, CM electrophysiological properties, diabetes disease progression, 
and inflammatory response.7 Within rodent models, it is also difficult to study how 
individual cell types respond in a diseased state. In cell culture, specific cell types can be 
investigated, but it lacks a dynamic 3D ECM environment.   
Recently, the field of tissue engineering has moved towards mimicking diseases by 
employing organotypic models that are physiologically relevant and reproducible, with 
the intent to study specific cell changes within a disease and determine definitive 
interactions to halt and reverse disease progression.17–19 Tissue engineering holds 
substantial promise for addressing these needs, as it encompasses a wide variety of 
disciplines and organotypic 3D models are attractive as they are controllable, repetitive, 
and more cost efficient than animal testing.11  
Other groups have attempted to bridge this gap for the study of DCMP but have failed to 
either produce a complex and dynamic 3D ECM environment or have utilized animal 
cells, instead of human cells.10,12,13 Within our lab we have produced a complex 3D 
acellular scaffold from decellularized porcine myocardium, which has been proven to 
retain mechanical and vascular integrity, and important ECM basal lamina components 
crucial to recapitulating native myocardium, such as fibronectin, laminin, and collagen 
IV.14 Myocardial ECM is very diverse and this specific environment is essential for 
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inherent cellular interactions and tethering.20,21 Cell – ECM interactions in DCMP are 
especially pivotal in this disease, as myocardial fibrosis causes CMs to overcompensate 
to contract the left ventricle, leading to CM death and hypertrophy.22  
Primary hCM progenitor cells have recently been used for research in areas such as 
cardiotoxicity, therapeutic testing, scaffold biocompatibility, and the study of pathways 
involved in oxidative stress.23–26 They are more cost effective than induced pluripotent 
stem cells (iPSCs), can proliferate, and express cardiac markers, such as sarcomeric α-
actin, making them ideal for CM investigation.27 We have shown these cells respond to 
biochemical cues, such as normal (1 g/L) and high (4.5 g/L) glucose, in their milieu (see 
Chapter 4). 
We examined two DCMP tissue engineering platforms generated within our lab. We 
chose to combine hCM and decellularized acellular porcine myocardium in either (1) a 
3D Kube perfusion minibioreactor or (2) an electromechanical bioreactor we developed. 
3D Kubes have been employed by researchers for disease modelling, tissue angiogenesis 
investigations, and cell differentiation and seeding studies.28–31 Our electromechanical 
bioreactor has been shown to not alter the CM phenotype or ECM in normal conditions 
(see Chapter 5). Each were able to be housed within separate incubators and supported 
viable hCM in these scaffolds for 14 days in either normal or high glucose conditions.  
To investigate these models, we explored some known hallmarks of DCMP. Within the 
hyperglycemic and dyslipidemic diabetic environment there is a loss of metabolic 
plasticity and cells rely mainly in free fatty acids for energy.32 This leads to lipid 
peroxidation and accumulation, as well as prolonged accrual of reactive oxygen species 
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with oxidative stress as antioxidant defense mechanisms are overwhelmed.33 In this 
prolonged state, there is an increase in, endoplasmic reticulum (ER) stress, autophagy, 
and apoptosis.34,35 Hyperglycemia also increases accumulation of irreversible crosslinks 
formed by AGEs and hindered MMP activity, leading to fibrosis.36   
In examining early MMP activity and AGE buildup, we saw no differences in overall 
MMP activity in media and AGE expression between the normal and high glucose groups 
in either bioreactor system. This could be due to the experimental duration of 14 days 
being too short to see noticeable changes in AGE accumulation from protein lysates and 
overall MMP activity in media. Media analysis could be useful for determining specific 
diagnostic markers for patient blood testing. There were no differences in overall MMP, 
MMP9, and active MMP2 activity in tissue lysates. We did however, see a significant 
increase in overall MMP2 and pro MMP2 activity in high glucose electromechanical 
tissue lysates. At this early point we may be seeing initial stages of unbalanced MMP 
activity, as MMP2 is heightened in inflammation, and we know later on, in established 
diabetic patients’ serum, MMPs are significantly lowered.37,38 We were able to see higher 
lipid accumulation within the high glucose tissue in both platforms.  This is promising as 
this is a trait of diabetes.39 
Cellular alterations in hCM such as endogenous antioxidant defense mechanisms, 
autophagy, apoptosis, and ER stress were inspected. SOD-2, an endogenous antioxidant 
defense mechanism, was slightly elevated in high glucose samples in both systems. 
Autophagy was significantly increased within the 3D Kube minibioreactor high glucose 
group and no difference was seen between groups in the electromechanical bioreactor. 
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Apoptosis was seen in both states in the minibioreactor system and there was a slight 
increase in apoptosis in the high glucose electromechanically conditioned samples. ER 
stress was only examined in the electromechanical platform and no differences were 
found between groups. In examining early changes, it is important to note that there are 
some alterations that may occur before others and some that may not occur until later 
stages DCMP. These changes occur over the course of years. Currently, our 
understanding of initial stages of this disease is limited and these results are promising as 
we know that within the cell, autophagy has been shown to be increased in 
hyperglycemia and after a prolonged state, it can lead to apoptosis.40 In evaluating longer 
timepoints with these models, we could determine specifically when these modifications 
in hCM are occurring in the progression of DCMP.  
While this 3D Kube minibioreactor is a promising model for DCMP, there are some 
drawbacks with this platform. Due to the small size of the 3D Kube chambers, protein 
extraction and analysis is limited, as is sample throughput. Even though this perfusion 
system is dynamic in nature, it lacks physiological myocardial conditions such as, 
electrical and mechanical stimuli. The electromechanical bioreactor provides these 
conditions; however, it is not a perfusion system and media must be changed every day to 
support cell viability. Because of this, changes in DCMP and diabetes may not have 
shown, as they are caused by accrual of proteins and toxic intermediates within the body.  
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6.5 Conclusions 
Currently, limitations in animal and cell culture models of DCMP constrain our 
understanding of early alterations of specific cell types in this disease. Elucidating initial 
modifications are important for targeted therapies and patient diagnosis. Tissue 
engineering can bridge this gap with controllable, reproducible, and cost-effective 
organotypic models. We were able to combine acellular porcine myocardium and hCM 
within (1) 3D Kube minibioreactors and (2) an electromechanical bioreactor with added 
glucose for a DCMP tissue engineered models. Within these disease models, some early 
alterations in hCM and ECM were seen. While these systems are promising on their own, 
a more appropriate platform could be developed by combining these two. 
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CHAPTER 7: CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE 
WORK 
 
7.1 CONCLUSIONS 
 As the epidemic of diabetes continues to rise, it follows that instances of 
cardiovascular disease, such as diabetic cardiomyopathy, hypertension, and 
atherosclerosis in diabetic patients also rise.1,2 Diabetic cardiomyopathy (DCMP) occurs 
in diabetic patients as a ventricular dysfunction independent of coronary artery disease, 
hypertension or valvular abnormalities.3 Through cascading events over time, 
hyperglycemia and dyslipidemia can lead to this myocardial disease. Dyslipidemia leads 
to heightened utilization of circulating free fatty acids (FFA) that creates a highly 
oxidative environment that supersedes the endogenous antioxidant defense mechanism of 
cells, preceding oxidative stress, lipotoxicity, autophagy, and apoptosis of 
cardiomyocytes.4 Hyperglycemia causes the formation and accumulation of advanced 
glycation endproducts (AGEs) in the extracellular matrix, leading to fibrosis. These 
alterations in the myocardium can lead to cardiac inefficiency and heart failure.5  
Currently, mainly rodent models and two dimensional (2D) cell cultures have 
been employed to analyze early changes associated with DCMP. However, there are 
notable differences between rodents and humans that provide challenges when studying 
DCMP and 2D cultures lack a dynamic, three dimensional (3D) environment crucial to 
the progression of this disease.6 As of now, DCMP diagnosis and treatment is lumped in 
with other cardiomyopathies and heart failure, with an emphasis on blood glucose 
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control.2 Treatments for this disease do not target the source of the problem, only treat the 
symptoms. A more accurate model is needed to investigate specific cell type early 
cellular and extracellular modifications of DCMP for diagnosis and determine and test 
potential therapies. We believe tissue engineering can be used to bridge this gap. The 
tissue engineering paradigm can be utilized to developing a reproducible, native-like 
tissue engineered model of the myocardium by combining a scaffold, cells, and 
biochemical and physical stimuli to model DCMP.  
We have shown that tools and methods used in our lab were able to detect known 
extracellular matrix (ECM) and cellular changes associated with DCMP in a 
streptozotocin (STZ) type 1 diabetic rat model. Furthermore, through examination of 
human cardiomyocytes (hCM), we were able to prove that these cells respond to 
hyperglycemia within their milieu. These techniques are useful for analyzing and 
detecting DCMP alterations in cells and the ECM such as, lipid accumulation, 
endogenous antioxidant mechanisms, advanced glycation endproduct (AGE) buildup, 
matrix metalloproteinase (MMP) activity, apoptosis, autophagy, endoplasmic reticulum 
(ER) stress, and perivascular and interstitial fibrosis.   
We produced a physiologically relevant electromechanical bioreactor within our 
lab and method for reproducible scaffolds from decellularized porcine myocardium. 
Through our in house decellularization procedure of whole porcine hearts, we were able 
to remove porcine cells efficiently while keeping important myocardial ECM proteins 
such as collagen IV and laminin intact. By designing and 3D printing a tissue slicer, 
myocardium was easily extracted for use. This myocardial scaffold supported viable 
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hCM for 18 days. Our electromechanical bioreactor sustained hCM seeded on and in 
these scaffolds for 14 days at mechanical and electrical physiological conditions. Cells 
were aligned, found throughout the scaffolds, and maintained the cardiomyocyte 
phenotype. The ECM was found to be unaltered in these dynamic conditions.  
We examined cardiac tissue engineered constructs in: (1) a perfusion 3D Kube 
minibioreactor and (2) the electromechanical bioreactor customized in our lab. Each 
platform contained decellularized myocardium seeded with human cardiomyocytes for 
two weeks; “diabetic” conditions were simulated by increased glucose concentration. 
Within these models some early alterations of DCMP were seen. We found were able to 
better mimic physiological conditions with our electromechanical bioreactor, compared 
to static and non-diabetic conditions, as well as to 2D cell culture.  
Our electromechanical tissue engineering platform shows promise for unveiling 
early cellular and matrix modifications in DCMP. The potential for this system is 
enormous; it could be useful for studying other cardiac diseases in many human cell 
types, testing potential therapies and drugs, and preconditioning tissue engineered 
myocardium prior to implantation. 
7.2 Project Challenges and Considerations 
Challenges in this project arose in seeding cells into decellularized porcine 
myocardium. Injection seeding of myocardium resulted in pockets of cells within the 
scaffold, which does not resemble the highly populated native myocardium. Dynamic 
stimulation, either perfusion or electromechanical, for the duration of 14 days did not 
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promote homogenous hCM migration into the scaffold. Cell seeding strategies are being 
investigated under other projects within our lab.  
Another challenge during this project was related to protein analysis of tissues 
cultured in the 3D Kube minibioreactor system. The tissue housed within 3D Kubes are 
very small and only so many cells can be seeded on them, this led to very low protein 
amounts. Protein lysates needed to be concentrated with spin columns before protein 
analysis with western blotting to be able to load 20ug per well. This limited proteins that 
were analyzed and led to a lower n-value. 
Our electromechanical bioreactor was able to house larger scaffolds seeded with 
hCM, which mitigated the protein analysis problem seen with the 3D Kube 
minibioreactor. This system, however, is not perfusion based, so media was changed 
every day. As DCMP and diabetes progress by the accumulation of proteins and toxic 
intermediates, this platform may not allow for early alterations in cells and the ECM to 
occur. This is currently being developed within our lab. 
A consideration for future DCMP models would include; the addition a known 
amount of lipids in media with the hyperglycemic environment to simulate dyslipidemia; 
increase in pressure to mimic hypertension; and addition of high cholesterol. Other 
Another consideration would be employing insulin to simulate a diabetic state with 
treatment to determine if cells are still altered. Fibroblasts should also be investigated in 
future research, as they are vital players in ECM turnover, are adversely affected in 
diabetes, and secrete important paracrine factors. More timepoints should be studied to 
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see when cellular and matrix changes are occurring. Microarrays for gene analysis would 
be useful for this. For a diagnostic potential, media should also be investigated for 
markers that could be targets for patient blood testing.   
7.3 Recommendations for Future Work 
7.3.1 Analysis of Perfusion Electromechanical Platform  
 The electromechanical bioreactor is now being modified to be perfusion based 
within our lab as of now. Testing of this platform will be performed to ensure hCM and 
human cardiac fibroblasts (FBs) maintain phenotype and the ECM is not adversely 
affected. hCM and FBs will be cultured and expanded until enough cells needed for 
seeding are reached. Decellularized porcine myocardium will be extracted with the tissue 
slicer, sterilized with peracetic acid, and left overnight in media (Dulbecco’s modified 
eagle medium, 10% fetal bovine serum, 1% antibiotic/antimycotic) at 37 degrees Celsius. 
Scaffolds will either be seeded with 3 million hCM or hFB per scaffold via dropwise and 
injection seeding. Some scaffolds will be seeded with both hCM (1.2 million; 40%) and 
hFB (1.8 million; 60%). Controls will have no cells. They will sit statically in the 
incubator for 1 hour, then 4mL of media will be added. Seeded scaffolds will remain in 
the incubator, static, for 3 days, with media changes each day. A PrestoBlue and 
live/dead assay will be performed as a checkpoint at this time.  
After this duration, scaffolds will be placed within modified 6-well plates of the 
perfusion electromechanical bioreactor system housed in an incubator and for two days 
will be subjected to a 0-40-0 mmHg waveform, followed by two days at 0-80-0 mmHg. 
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Once this conditioning period is complete, myocardial-like tissue will be exposed to the 
0-120-0 mmHg waveform with electrical stimulus. Static scaffolds in 6 well plates will 
be run in tandem as a control with 4mL of media changed every two days. Media in the 
electromechanical perfusion system will be changed once a week with supplemental 
antibiotic injections 3.5 days after media changes. Media will be collected from static and 
dynamic groups every week and frozen for examination.  
Static or Dynamic Cells on Scaffold Histology; Protein; RNA PrestoBlue & Live/Dead
Static hCM 5 1
Static hFB 5 1
Static hCM + hFB 5 1
Static No cells 5 1
Dynamic hCM 5 1
Dynamic hFB 5 1
Dynamic hCM + hFB 5 1
Dynamic No cells 5 1
Perfusion Electromechanical Bioreactor 
Samples Per Timepoint (2,4,6,8 weeks)Groups
 
Table 7.1: Sample analysis of perfusion electromechanical bioreactor.  
 
Figure 7.1: Diagram of dissection of scaffolds for analysis. 
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Timepoints analyzed will be two, four, six, and eight weeks. In order to have a 
high and desired n-value outlined in Table 7.1, this experiment will need to be performed 
four times. One myocardial-like tissue from each group will be assessed by PrestoBlue 
and a live/dead assay to determine cell viability at each timepoint. Scaffolds will be 
dissected as shown in Figure 7.1. Half of each scaffold will be placed in 10% formalin 
for 48 hours, processed, embedded, and sectioned to 5um on slides. Slides will be stained 
with hematoxylin and eosin, Movat’s pentachrome, Masson’s trichrome, and 
immunohistochemically stained for: cardiomyocyte markers such as, sarcomeric α-
actinin, connexin 43, desmin, and GATA-4; fibroblast markers such as vimentin, prolyl 
4-hydroxylase, and heat shock protein 47; and ECM proteins such as, collagen IV and 
laminin. One-fourth of each myocardial-like tissue will be used for protein isolation and 
flash frozen before stored in the -80-degree Celsius freezer until extraction via 
homogenizer and radioimmunoprecipitation assay (RIPA) buffer. Total protein from 
these samples will be determined by bicinchoninic acid (BCA) assay. Western blotting 
protein for cardiomyocyte markers such as, sarcomeric α-actinin, connexin 43, desmin, 
and GATA-4, and ECM proteins such as, collagen IV and laminin will be investigated. 
Matrix metalloproteinase (MMP) activity will be examined in media and lysates by 
gelatin zymography. One-fourth of each scaffold will be flash frozen and stored in -80-
degree Celsius freezer for ribonucleic acid (RNA) isolation. RNA samples will be sent 
away for microarray analysis for cardiomyocyte genes such as, GATA4 and myosin 
heavy chain-β; fibroblast genes such as, vimentin, collagen I and III, and fibroblast 
specific protein 1; and any other genes of interest.  
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7.3.2 Preliminary Dyslipidemic and High Cholesterol Testing 
 Preliminary testing of addition of FFAs and cholesterol will be performed to 
determine if they harm cell viability in culture. hCM and hFBs will need to be cultured in 
serum free conditions, so known amounts of cholesterol and FFAs can be added. hCM 
and hFBs (2:3 seeding ratio), hCM alone, and hFB alone will be cultured in 48 well 
plates and subjected to various conditions for 12, 24, 48, and 72 hour, and 1 and 2 week 
timepoints for viability and cytotoxicity with PrestoBlue, live/dead, and MTS assays. 
Cholesterol (Sigma-Aldrich, catalogue #: C3045) will be dissolved in ethanol and added 
to serum free media in a range of normal at 1g/L (100mg/dL) to high at 2.5g/L 
(250mg/dL) cholesterol. Palmitic acid (Sigma-Aldrich, catalogue #: P0500) and oleic 
acid (Sigma-Aldrich, catalogue #: O1008), main fatty acids in human nutrition, will be 
conjugated to bovine serum albumin and added to serum free media in a range from 
0.25mmol/L to 0.5mmol/L, as previously studied.7 Final concentrations in media will be 
assessed after sterile filtration with colorimetric enzymatic assays LabAssay™ 
Cholesterol and LabAssay™ Phospholipid (FUJIFILM, Wanko Chemicals) before 
addition to cells. Conditions and analysis will be performed as shown in Figure 7.2 and 
Figure 7.3. 
Once testing determines optimal high and normal concentrations of cholesterol 
and FFAs in cell culture, secondary preliminary testing will assess these in the two cell 
types (hCM + hFB, hCM, and hFB) with combinations of these in normal (1g/L) and 
high (4.5g/L) glucose at the same timepoints (12, 24, 48, and 72 hours, and 1 and 2 
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weeks). Cell viability and cytotoxicity with be analyzed with PrestoBlue, live/dead, and 
MTS assays at these timepoints as shown in Figure 7.4.  
 
Figure 7.2: 48 well plate layout of cholesterol testing. One plate for each timepoint and one cell 
type or combination. MTS=MTS assay. L/D=live/dead. PB=PrestoBlue.  
 
Figure 7.2: 48 well plate layout of FFA testing. One plate for each timepoint and one cell type or 
combination. MTS=MTS assay. L/D=live/dead. PB=PrestoBlue.  
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Figure 7.4: 48 well plate layout of combinational testing. One plate for each timepoint and one 
cell type or combination. MTS=MTS assay. L/D=live/dead. PB=PrestoBlue.  
7.3.3 Perfusion Electromechanical Platform: DCMP Model 
 The same dynamic experimental setup described in 7.3.1 will be used, however in 
order to model a “diabetic” environment, glucose will be added (4.5 g/L), along with high 
FFAs and cholesterol (determined in 7.3.2) to serum free media in the perfused 
electromechanical bioreactor. Normal serum free media (1 g/L glucose, normal FFAs and 
cholesterol) will be run in tandem as a control. All scaffolds seeded with hCM, hFB, and 
hCM and hFB will be conditioned as described before, then subjected to physiological 
conditions in the perfused electromechanical system. Timepoints analyzed will be two, 
four, six, and eight weeks at normal and “diabetic” conditions for all three cell groups 
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(Table 7.2). Media will also be collected and samples at two, four, six, and eight weeks 
will be analyzed. Multiple bioreactor runs will be done for a high n-value and separate 
runs will be done for normal and “diabetic” conditions. A total of 8 runs will be 
performed (normal vs. “diabetic” at four timepoints). A PrestoBlue and live/dead assay 
will be used to determine cell viability at these timepoints in normal and “diabetic” 
groups. Myocardial-like tissue will be saved for paraffin and frozen cryosection 
histological staining, protein, and RNA analysis as shown in Figure 7.1 and Table 7.2. 
Examination of DCMP hallmarks such as lipid accumulation, endogenous antioxidant 
mechanisms, AGE buildup, MMP activity, apoptosis, autophagy, ER stress, and fibrosis 
will be completed as detailed in Chapter 6. Tissue and media will be sent away for 
microRNA analysis.  
Condition Cells on Scaffold Histology; Protein; RNA PrestoBlue & Live/Dead
1 Normal hCM 7 1
1 Normal hFB 7 1
1 Normal hCM + hFB 7 1
2 "Diabetic" hCM 7 1
2 "Diabetic" hFB 7 1
2 "Diabetic" hCM + hFB 7 1
Groups Samples Per Timepoint (2,4,6,8 weeks)
Perfusion Electromechanical Bioreactor 
Run
 
Table 7.2: Sample analysis of perfusion electromechanical bioreactor DCMP model.  
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Appendix A 
Abbreviations 
2D   two dimensional 
3D   three dimensional 
ABS   acrylonitrile butadiene styrene 
ACE   angiotensin converting enzyme 
ADSC   adipose derived stem cell 
AGE   advanced glycation endproduct 
Akt   protein kinase B 
ATF4   activating transcription factor 4 
ATF6   activating transcription factor 6 
ATP   adenosine 5’-triphosphate 
BCA   bicinchoninic acid protein assay 
BiP   binding protein 
BMDSC  bone marrow derived stem cell 
CD36   cluster of differentiation 36 
CHOP   CCAAT/-enhancer-binding protein homologous protein  
CM   cardiomyocyte 
cm   centimeters 
CML    carboxymethyl lysine 
CPC   cardiac progenitor cell 
CSC   cardiac stem cell 
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DAPI   4’,6-diamidino-2-phenylindole 
DAQ   data acquisition  
DCMP   diabetic cardiomyopathy 
ddH2O   distilled deionized water 
Decell   decellularization 
DMEM  Dulbecco’s modified eagle medium 
DNA   deoxyribonucleic acid 
DPP-4   dipeptidyl peptidase inhibitor 
DSC2   desmocollin-2 
EC   endothelial cell 
ECM   extracellular matrix 
EDTA   Ethylenediaminetetraacetic acid 
eIF2α   eukaryotic translation initiation factor 2 alpha 
eNOs   endothelial nitric oxide synthases 
EPC   endothelial progenitor cell 
ER   endoplasmic reticulum 
ERAD   endoplasmic reticulum associated degradation 
ESC   embryonic stem cell 
FB   fibroblast 
FBS   fetal bovine serum 
FFA   free fatty acid 
g   gram 
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GFP   green fluorescent protein 
GLP-1   glucagon-like peptide 1 
GLUT4  glucose transporter 4 
H&E    hematoxylin and eosin 
HCl   hydrochloric acid 
hCM   human cardiomyocyte 
Hz   hertz 
ICa-L   L-type calcium ion channel 
IHC   immunohistochemistry 
iPSC   induced pluripotent stem cell 
IRE-1   inositol-requiring enzyme 1 
IRS-1   insulin receptor substrate 1 
Ito   outward potassium current 
JNK   Jun N terminal kinase 
JUP   armadillo proteins plakiglobin 
L   liter 
LC3B   light chain 3B 
min   minute 
mL   milliliter 
mM   millimolar  
mmHg   millimeter of mercury 
MMP   matrix metalloproteinase 
 187 
MRI   magnetic resonance imaging 
MSC   mesenchymal stem cell 
msec   millisecond 
NaCl   sodium chloride 
NADPH  nicotinamide adenine dinucleotide phosphate 
NCX   Na+2/Ca+2 exchanger 
NIH   National Institute of Health 
NOS   nitric oxide synthase 
Nrf2   (erythroid-derived 2)-related factor2  
OCT   optimal cutting temperature  
PDK4   pyruvate dehydrogenase kinase 4 
PERK   protein kinase RNA-like ER kinase 
PET    positron emission tomography 
PI3K    phosphoinositide 3-kinase  
PKC   protein kinase C 
PLB   phosphorylated phospholamban 
PPAR- α  peroxisome proliferator-activated receptor alpha 
RAGE   receptor for advanced glycation endproducts 
RDU   relative densitometry units 
RGD   arginylglycylaspartic acid 
RIPA   Radioimmunoprecipitation assay 
RNA   ribonucleic acid 
 188 
ROS    reactive oxygen species 
RyRs   ryanodine receptor 
sarc. α-actinin  sarcomeric α-actinin  
SD   standard deviation 
SDS   sodium dodecyl sulfate 
SEM    scanning electron microscopy 
SERCA  sarcoplasmic/endoplasmic reticulum Ca+2-ATPase 
SMC   smooth muscle cell 
SOD   superoxide dismutase 
STZ   streptozotocin 
TGF-β   transforming growth factor-beta 
TIMP   tissue inhibitor of matrix metalloproteinase 
TNFα    tumor necrosis factor alpha 
Tris   tris(hydroxymethyl)aminomethane 
TZD   thiazolindinediones 
ug   microgram  
um   micrometer 
UPR   unfolded protein response 
UV   ultraviolet 
V   volts 
XPB-1   X-box binding protein 1 
ZDF   Zucker diabetic fatty rat 
 189 
α   alpha  
α-SMactin  alpha smooth muscle actin 
 
 
 
 
 
